

Summary of Drinking Water Carcinogenicity Study
of 2-Aminoethanol
in F344 Rats

June 2010

Japan Bioassay Research Center

Japan Industrial Safety and Health Association

PREFACE

The tests were contracted and supported by the Ministry of Health, Labour and Welfare of Japan. The tests were conducted by Japan Bioassay Research Center (JBRC) and the report was prepared by JBRC and peer reviewed by outside expert pathologist. Complete report was submitted to Ministry of Health, Labour and Welfare of Japan on June 29, 2010.

This English Summary was translated by JBRC from Japanese complete report.

Summary of Drinking Water Carcinogenicity Study of 2-Aminoethanol in F344 Rats

Purpose, materials and methods

2-Aminoethanol (CAS No. 141-43-5) is a colorless clear viscosity liquid with a melting point of 10.3°C. It is soluble in water, methanol, and acetone.

The carcinogenicity and chronic toxicity of 2-aminoethanol were examined in F344/DuCrIj rats. Groups of test animals were administered 2-aminoethanol in their drinking water for 2 years (104 weeks). Each group consisted of either 50 male or 50 female rats. The drinking water concentrations of 2-aminoethanol were 0, 800, 2400 or 7200 ppm (w/w). Both sexes were administered each concentration of 2-aminoethanol. The highest dose level was chosen so as not to exceed the maximum tolerated dose (MTD), based on both growth rate and toxicity in a previous 13-week toxicity study. The identity of the 2-aminoethanol used in these experiments was confirmed by both infrared spectrometry and mass spectrometry, and it was analyzed by high performance liquid chromatography before and after its use to affirm its stability. The concentrations of 2-aminoethanol in the drinking water were determined by high performance liquid chromatography at the time of preparation and on the 4th day after preparation while stored at room temperature. The animals were observed daily for clinical signs and mortality. Body weight, water consumption and food consumption were measured once a week for the first 14 weeks and every 4 weeks thereafter. Animals found dead, in a moribund state, or surviving to the end of the 2-year administration period underwent complete necropsy. Urinalysis was performed near the end of the administration period. Hematology and blood biochemistry analysis were performed at the terminal necropsy: surviving animals were fasted overnight and bled under deep ether anesthesia. Organs and tissues were removed, weighed and examined for macroscopic lesions at necropsy. The organs and tissues were then fixed and embedded in paraffin. Five μm thick tissue sections were prepared and stained with hematoxylin and eosin and examined microscopically. Incidences of neoplastic lesions were statistically analyzed by Fisher's exact test. Any positive dose-response trends of 2-aminoethanol induction of neoplastic lesions were analyzed by Peto's test. Incidences of non-neoplastic lesions and urinalysis were analyzed by the Chi-square test. Changes in body weight, water consumption, food consumption, hematological and blood biochemical parameters, and organ weights were analyzed by Dunnett's test. The present studies were conducted in

accordance with the Organisation for Economic Co-operation and Development (OECD) Good Laboratory Practice and with reference to the OECD Guideline for Testing of Chemicals 451 “Carcinogenicity Studies”.

Results

The survival rate of the females administered 7200 ppm 2-aminoethanol was slightly decreased, however, the decreased survival rate was not causally related to the administration of the test substance. There was no significant difference in survival rates between any other 2-aminoethanol-administered groups and their controls. Soiled fur around the genitalia and brown and red urine were observed in the 7200 ppm-administered females. Growth rates of the males and females administered 7200 ppm 2-aminoethanol were suppressed. Food consumption was decreased in the males administered 7200 ppm 2-aminoethanol throughout most of the 2-year administration period. Water consumption was decreased in the males and females administered 7200 ppm 2-aminoethanol throughout most of the 2-year administration period, and was decreased sporadically in the males administered 2400 ppm 2-aminoethanol during the 2-year administration period. Mean corpuscular volume and reticulocyte were significantly decreased in males administered 7200 ppm 2-aminoethanol. Significant decreases in total red blood cells, hematocrit, and total lymphocytes and significant increases in platelets, reticulocyte, and neutrophil leukocytes were observed in females administered 7200 ppm 2-aminoethanol.

No significant increases in the incidence of neoplastic or tumor-related lesions was found in any of the 2-aminoethanol-administered groups of either sex. Renal papillary necrosis in males and females administered 2400 and 7200 ppm 2-aminoethanol were significantly increased and urothelial hyperplasia of the pelvis was significantly increased in the females administered 7200 ppm 2-aminoethanol. Kidney weights were significantly increased in the males administered 7200 ppm 2-aminoethanol and in the females administered 2400 and 7200 ppm 2-aminoethanol. Urinary occult blood and urea nitrogen in the plasma were increased in females administered 2400 and 7200 ppm 2-aminoethanol.

Using kidney weight and renal lesions as endpoint markers, the no-observed-adverse-effect-level (NOAEL) for both males and females of 2-aminoethanol in the drinking water was 800 ppm (male: 42 mg/kg body weight per day, female: 69 mg/kg body weight per day).

Conclusions

There was no evidence for carcinogenicity of 2-aminoethanol in male or female rats.

Incidences of selected neoplastic lesions of male rats in the 2-year drinking water carcinogenicity study of 2-aminoethanol

Dose (ppm)		0	800	2400	7200	Peto test	Cochran-Armitage test
Number of examined animals		50 ^{a)}	50	50	50		
benign tumor							
skin/appendage	squamous cell papilloma	4	0	1	0		
	keratoacanthoma	6	2	2	1		
subcutis	fibroma	6	1	6	4		
pancreas	islet cell adenoma	3	5	2	4		
pituitary	adenoma	13	7	6	8		
thyroid	C-cell adenoma	12	12	8	7		
adrenal	pheochromocytoma	4	4	3	5		
testis	interstitial cell tumor	35	31	31	20 **		↓ ↓
malignant tumor							
spleen	mononuclear cell leukemia	4	2	7	0		
pancreas	islet cell adenocarcinoma	1	3	1	3		
pituitary	adenocarcinoma	1	1	2	3		

Incidences of selected neoplastic lesions of female rats in the 2-year drinking water carcinogenicity study of 2-aminoethanol

Dose (ppm)		0	800	2400	7200	Peto test	Cochran-Armitage test
Number of examined animals		50	50	50	50		
benign tumor							
pituitary	adenoma	12	17	16	14		
thyroid	C-cell adenoma	6	8	11	4		
adrenal	pheochromocytoma	1	1	1	3		
uterus	endometrial stromal polyp	7	5	9	5		
mammary gland	fibroadenoma	7	7	10	4		
clitoral gland	adenoma	3	3	1	2		
malignant tumor							
spleen	mononuclear cell leukemia	4	7	5	5		
adrenal	pheochromocytoma: malignant	0	0	0	1		
adrenal	pheochromocytoma (benign+malignant)	1	1	1	4	↑ ^{b)}	

^{a)}: Numer of examined animal of pituitary is 49. ^{b)}: Significant in prevalence method only.

Significant difference

* : $p \leq 0.05$

** : $p \leq 0.01$

(Fisher test)

↑ : $p \leq 0.05$ increase

↑ ↑ : $p \leq 0.01$ increase

(Peto, Cochran-Armitage test)

↓ : $p \leq 0.05$ decrease

↓ ↓ : $p \leq 0.01$ decrease

(Cochran-Armitage test)

SELECTED TABLES

TABLE C 1 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS:
MALE

TABLE C 2 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS:
FEMALE

TABLE C 3 BODY WEIGHT CHANGES: MALE

TABLE C 4 BODY WEIGHT CHANGES: FEMALE

TABLE D 1 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL
NUMBERS: MALE

TABLE D 2 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL
NUMBERS: FEMALE

TABLE D 3 FOOD CONSUMPTION CHANGES: MALE

TABLE D 4 FOOD CONSUMPTION CHANGES: FEMALE

TABLE E 1 WATER CONSUMPTION CHANGES AND SURVIVAL ANIMAL
NUMBERS: MALE

TABLE E 2 WATER CONSUMPTION CHANGES AND SURVIVAL ANIMAL
NUMBERS: FEMALE

TABLE E 3 WATER CONSUMPTION CHANGES: MALE

TABLE E 4 WATER CONSUMPTION CHANGES: FEMALE

TABLE F 1 CHEMICAL INTAKE CHANGES: MALE

TABLE F 2 CHEMICAL INTAKE CHANGES: FEMALE

TABLE G 1 HEMATOLOGY: MALE

TABLE G 2 HEMATOLOGY: FEMALE

TABLE H 1 BIOCHEMISTRY: MALE

TABLE H 2 BIOCHEMISTRY: FEMALE

SELECTED TABLES (CONTINUED)

TABLE I 1 URINALYSIS: MALE

TABLE I 2 URINALYSIS: FEMALE

TABLE K 1 ORGAN WEIGHT, ABSOLUTE: MALE

TABLE K 2 ORGAN WEIGHT, ABSOLUTE: FEMALE

TABLE L 1 ORGAN WEIGHT, RELATIVE: MALE

TABLE L 2 ORGAN WEIGHT, RELATIVE: FEMALE

TABLE M 1 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS:
MALE: ALL ANIMALSTABLE M 4 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS:
FEMALE: ALL ANIMALSTABLE P 1 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS:
MALETABLE P 2 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS:
FEMALETABLE R HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: F344/DuCr1Cr1j
FEMALE RATS

TABLE S 1 CAUSE OF DEATH: MALE

TABLE S 2 CAUSE OF DEATH: FEMALE

TABLE C 1

BODY WEIGHT CHANGES AND
SURVIVAL ANIMAL NUMBERS: MALE

Week-Day on Study	Control			800 μm			2400 μm			7200 μm		
	Av. Wt.	No. of Surviv. <50>	Av. Wt.	% of cont. <50>	No. of Surviv.	Av. Wt.	% of cont. <50>	No. of Surviv.	Av. Wt.	% of cont. <50>	No. of Surviv.	
0-0	121 (50)	50/50	121 (50)	100	50/50	121 (50)	100	50/50	121 (50)	100	50/50	
1-7	150 (50)	50/50	149 (50)	99	50/50	149 (50)	99	50/50	141 (50)	94	50/50	
2-7	181 (50)	50/50	179 (50)	99	50/50	179 (50)	99	50/50	170 (50)	94	50/50	
3-7	206 (50)	50/50	204 (50)	99	50/50	205 (50)	100	50/50	194 (50)	94	50/50	
4-7	225 (50)	50/50	224 (50)	100	50/50	225 (50)	100	50/50	214 (50)	95	50/50	
5-7	240 (50)	50/50	239 (50)	100	50/50	241 (50)	100	50/50	229 (50)	95	50/50	
6-7	253 (50)	50/50	252 (50)	100	50/50	254 (50)	100	50/50	241 (50)	95	50/50	
7-7	264 (50)	50/50	263 (50)	100	50/50	265 (50)	100	50/50	252 (50)	95	50/50	
8-7	274 (50)	50/50	273 (50)	100	50/50	274 (50)	100	50/50	260 (50)	95	50/50	
9-7	283 (50)	50/50	282 (50)	100	50/50	282 (50)	100	50/50	266 (50)	94	50/50	
10-7	290 (50)	50/50	291 (50)	100	50/50	290 (50)	100	50/50	273 (50)	94	50/50	
11-7	296 (50)	50/50	299 (50)	101	50/50	299 (50)	101	50/50	279 (50)	94	50/50	
12-7	303 (50)	50/50	306 (50)	101	50/50	305 (50)	101	50/50	285 (50)	94	50/50	
13-7	309 (50)	50/50	312 (50)	101	50/50	312 (50)	101	50/50	290 (50)	94	50/50	
14-7	315 (50)	50/50	318 (50)	101	50/50	317 (50)	101	50/50	295 (50)	94	50/50	
18-7	333 (50)	50/50	336 (50)	101	50/50	334 (50)	100	50/50	309 (50)	93	50/50	
22-7	347 (50)	50/50	350 (50)	101	50/50	348 (50)	100	50/50	320 (50)	92	50/50	
26-7	359 (50)	50/50	362 (50)	101	50/50	360 (50)	100	50/50	329 (50)	92	50/50	
30-7	372 (50)	50/50	373 (50)	100	50/50	370 (50)	99	50/50	337 (50)	91	50/50	
34-7	382 (50)	50/50	385 (49)	101	49/50	380 (50)	99	50/50	345 (50)	90	50/50	
38-7	390 (50)	50/50	394 (49)	101	49/50	388 (50)	99	50/50	351 (50)	90	50/50	
42-7	396 (50)	50/50	401 (49)	101	49/50	394 (50)	99	50/50	356 (50)	90	50/50	
46-7	404 (49)	49/50	406 (49)	100	49/50	399 (50)	99	50/50	359 (50)	89	50/50	
50-7	411 (49)	49/50	411 (49)	100	49/50	405 (50)	99	50/50	363 (50)	88	50/50	
54-7	417 (49)	49/50	418 (49)	100	49/50	410 (50)	98	50/50	366 (50)	88	50/50	
58-7	422 (49)	49/50	424 (49)	100	49/50	416 (50)	99	50/50	369 (50)	87	50/50	
62-7	430 (48)	48/50	430 (49)	100	49/50	421 (50)	98	50/50	374 (50)	87	50/50	
66-7	434 (48)	48/50	435 (49)	100	49/50	426 (50)	98	50/50	377 (50)	87	50/50	
70-7	438 (47)	47/50	434 (49)	99	49/50	429 (50)	98	50/50	379 (50)	87	50/50	
74-7	440 (47)	47/50	434 (49)	99	49/50	433 (50)	98	50/50	379 (50)	86	50/50	
78-7	443 (47)	47/50	442 (47)	100	47/50	433 (50)	98	50/50	385 (48)	87	48/50	
82-7	447 (47)	47/50	446 (47)	100	47/50	436 (47)	98	47/50	385 (48)	86	48/50	
86-7	440 (46)	46/50	448 (47)	102	47/50	437 (47)	99	47/50	386 (48)	88	48/50	
90-7	438 (45)	45/50	448 (47)	102	47/50	439 (45)	100	45/50	383 (48)	87	48/50	
94-7	435 (44)	44/50	444 (47)	102	47/50	436 (42)	100	42/50	386 (45)	89	45/50	
98-7	434 (42)	42/50	441 (46)	102	46/50	435 (42)	100	42/50	386 (44)	89	41/50	
102-7	428 (41)	41/50	433 (46)	101	46/50	439 (40)	103	40/50	386 (41)	90	41/50	
104-7	428 (40)	40/50	426 (45)	100	45/50	431 (38)	101	38/50	387 (40)	90	40/50	

< : No. of effective animals, () : No. of measured animals

Av. Wt. : g

(B10040)

BALS 4

TABLE C 2

BODY WEIGHT CHANGES AND
SURVIVAL ANIMAL NUMBERS: FEMALE

STUDY NO. : 0641
ANIMAL : RAT F344/DuCrIjCrIj[F344/DuCrj]
UNIT : g
REPORT TYPE : AI 104
SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

PAGE : 2

Control				800 ppm				2400 ppm				7200 ppm			
Week-Day on Study	Av. Wt.	No. of Surviv.	Av. Wt.	% of cont.	No. of Surviv.	Av. Wt.	% of cont.	No. of Surviv.	Av. Wt.	% of cont.	No. of Surviv.	Av. Wt.	% of cont.	No. of Surviv.	Av. Wt.
0-0	100 (50)	50/50	100 (50)	100	50/50	100 (50)	100	50/50	100 (50)	100	50/50	100 (50)	100	50/50	100 (50)
1-7	116 (50)	50/50	115 (50)	99	50/50	115 (50)	99	50/50	115 (50)	99	50/50	110 (50)	95	50/50	110 (50)
2-7	128 (50)	50/50	127 (50)	99	50/50	128 (50)	100	50/50	128 (50)	100	50/50	123 (50)	96	50/50	123 (50)
3-7	137 (50)	50/50	135 (50)	99	50/50	135 (50)	99	50/50	135 (50)	99	50/50	132 (50)	96	50/50	132 (50)
4-7	145 (50)	50/50	143 (50)	99	50/50	144 (50)	99	50/50	144 (50)	99	50/50	138 (50)	95	50/50	138 (50)
5-7	150 (50)	50/50	149 (50)	99	50/50	149 (50)	99	50/50	149 (50)	99	50/50	144 (50)	96	50/50	144 (50)
6-7	155 (50)	50/50	154 (50)	99	50/50	155 (50)	100	50/50	155 (50)	100	50/50	148 (50)	95	50/50	148 (50)
7-7	160 (50)	50/50	158 (50)	99	50/50	159 (50)	99	50/50	159 (50)	99	50/50	152 (50)	95	50/50	152 (50)
8-7	164 (50)	50/50	162 (50)	99	50/50	163 (50)	99	50/50	163 (50)	99	50/50	156 (50)	95	50/50	156 (50)
9-7	167 (50)	50/50	165 (50)	99	50/50	166 (50)	99	50/50	166 (50)	99	50/50	159 (50)	95	50/50	159 (50)
10-7	171 (50)	50/50	168 (50)	98	50/50	170 (50)	99	50/50	170 (50)	99	50/50	162 (50)	95	50/50	162 (50)
11-7	173 (50)	50/50	172 (50)	99	50/50	173 (50)	100	50/50	173 (50)	100	50/50	165 (50)	95	50/50	165 (50)
12-7	177 (50)	50/50	176 (50)	99	50/50	176 (50)	99	50/50	176 (50)	99	50/50	167 (50)	94	50/50	167 (50)
13-7	178 (50)	50/50	177 (50)	99	50/50	178 (50)	100	50/50	178 (50)	100	50/50	169 (50)	95	50/50	169 (50)
14-7	180 (50)	50/50	179 (50)	99	50/50	180 (50)	100	50/50	180 (50)	100	50/50	170 (50)	94	50/50	170 (50)
18-7	186 (50)	50/50	187 (50)	101	50/50	188 (50)	101	50/50	188 (50)	101	50/50	176 (50)	95	50/50	176 (50)
22-7	191 (50)	50/50	192 (50)	101	50/50	193 (50)	101	50/50	193 (50)	101	50/50	180 (50)	94	50/50	180 (50)
26-7	196 (50)	50/50	197 (50)	101	50/50	199 (50)	102	50/50	199 (50)	102	50/50	185 (50)	94	50/50	185 (50)
30-7	202 (50)	50/50	203 (50)	100	50/50	205 (50)	101	50/50	205 (50)	101	50/50	189 (50)	94	50/50	189 (50)
34-7	207 (50)	50/50	210 (50)	101	50/50	210 (50)	101	50/50	210 (50)	101	50/50	192 (50)	93	50/50	192 (50)
38-7	210 (50)	50/50	213 (50)	101	50/50	213 (50)	101	50/50	213 (50)	101	50/50	195 (49)	93	49/50	195 (49)
42-7	215 (50)	50/50	218 (50)	101	50/50	219 (50)	102	50/50	219 (50)	102	50/50	199 (49)	93	49/50	199 (49)
46-7	218 (50)	50/50	221 (50)	101	50/50	222 (50)	102	50/50	222 (50)	102	50/50	201 (49)	92	49/50	201 (49)
50-7	224 (50)	50/50	226 (50)	101	50/50	226 (50)	101	50/50	226 (50)	101	50/50	203 (49)	91	49/50	203 (49)
54-7	227 (50)	50/50	230 (50)	101	50/50	230 (50)	101	50/50	230 (50)	101	50/50	207 (49)	91	49/50	207 (49)
58-7	231 (50)	50/50	234 (50)	101	50/50	234 (50)	101	50/50	234 (50)	101	50/50	209 (49)	90	49/50	209 (49)
62-7	238 (50)	50/50	241 (50)	101	50/50	243 (50)	102	50/50	243 (50)	102	50/50	212 (49)	89	49/50	212 (49)
66-7	244 (50)	50/50	247 (49)	101	49/50	249 (50)	102	50/50	249 (50)	102	50/50	217 (47)	88	47/50	217 (47)
70-7	250 (50)	50/50	253 (49)	101	49/50	254 (50)	102	50/50	254 (50)	102	50/50	219 (47)	88	47/50	219 (47)
74-7	255 (50)	50/50	258 (49)	101	49/50	259 (50)	102	50/50	259 (50)	102	50/50	222 (46)	87	46/50	222 (46)
78-7	261 (50)	50/50	264 (48)	101	48/50	264 (50)	101	50/50	264 (50)	101	50/50	223 (44)	85	44/50	223 (44)
82-7	265 (49)	49/50	270 (46)	102	46/50	275 (50)	102	50/50	275 (50)	102	50/50	227 (42)	85	42/50	227 (42)
86-7	267 (49)	49/50	273 (44)	102	44/50	274 (49)	100	49/50	274 (49)	100	49/50	232 (38)	85	38/50	232 (38)
90-7	273 (48)	48/50	280 (43)	103	43/50	281 (48)	101	48/50	281 (48)	101	48/50	230 (38)	83	38/50	230 (38)
94-7	278 (46)	46/50	284 (43)	102	43/50	284 (46)	101	42/50	284 (46)	101	42/50	227 (36)	81	36/50	227 (36)
98-7	279 (44)	44/50	284 (42)	102	42/50	284 (44)	101	44/50	284 (44)	101	44/50	222 (35)	79	35/50	222 (35)
102-7	280 (40)	40/50	285 (39)	102	39/50	285 (40)	101	38/50	285 (40)	101	38/50	221 (33)	79	33/50	221 (33)
104-7	280 (38)	38/50	281 (38)	100	38/50	283 (42)	101	42/50	283 (42)	101	42/50	221 (33)	79	33/50	221 (33)

< >:No. of effective animals, () :No. of measured animals

Av. Wt.: g

(B10040)

BAIS 4

TABLE C 3

BODY WEIGHT CHANGES: MALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r11[F344/DuCr11]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : MALE

PAGE : 1

BODY WEIGHT CHANGES
 ALL ANIMALS

Group Name	Administration week day					
	0-0	1-7	2-7	3-7	4-7	5-7
Control	121 ± 5	150 ± 7	181 ± 9	206 ± 11	225 ± 12	240 ± 13
800 ppm	121 ± 5	149 ± 7	179 ± 11	204 ± 12	224 ± 14	239 ± 14
2400 ppm	121 ± 5	149 ± 7	179 ± 10	205 ± 11	225 ± 12	241 ± 13
7200 ppm	121 ± 5	141 ± 7**	170 ± 10**	194 ± 12**	214 ± 12**	229 ± 13**

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett

(HAN260)

BATS 4

Group Name	Administration week day					
	7-7	8-7	9-7	10-7	11-7	12-7
Control	264± 15	274± 16	283± 16	290± 16	296± 18	303± 18
800 ppm	263± 17	273± 18	282± 17	291± 18	299± 18	306± 18
2400 ppm	265± 15	274± 15	282± 16	290± 16	299± 16	305± 17
7200 ppm	252± 13**	260± 14**	266± 14**	273± 15**	279± 16**	285± 16**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01						
Test of Dunnett						
(HAN260)						
BATS 4						

Group Name	Administration week day					Test of Dunnett	BATS 4
	14-7	18-7	22-7	26-7	30-7		
Control	315 ± 19	333 ± 19	347 ± 21	359 ± 21	372 ± 22	382 ± 24	390 ± 26
800 ppm	318 ± 17	336 ± 17	350 ± 18	362 ± 19	373 ± 19	385 ± 20	394 ± 20
2400 ppm	317 ± 17	334 ± 18	348 ± 19	360 ± 21	370 ± 21	380 ± 22	388 ± 23
7200 ppm	295 ± 16**	309 ± 17**	320 ± 19**	329 ± 20**	337 ± 22**	345 ± 23**	351 ± 24**

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 UNIT : 8
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 4

Group Name	Administration week-day							BODY WEIGHT CHANGES ALL ANIMALS		(SUMMARY)	
	42-7	46-7	50-7	54-7	58-7	62-7	66-7				
Control	396 ± 27	404 ± 24	411 ± 23	417 ± 23	422 ± 23	430 ± 23	434 ± 26				
800 ppm	401 ± 21	406 ± 22	411 ± 24	418 ± 23	424 ± 23	430 ± 24	435 ± 24				
2400 ppm	394 ± 24	399 ± 25	405 ± 26	410 ± 26	416 ± 27	421 ± 27	426 ± 28				
7200 ppm	356 ± 25**	359 ± 27**	363 ± 29**	366 ± 28**	369 ± 31**	374 ± 29**	377 ± 31**				
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01											
Test of Dunnett											
(HAN260)											
BATS 4											

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 UNIT : R
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 5

GROUP WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week-day				
	70-7	74-7	78-7	82-7	90-7
Control	438 ± 23	440 ± 24	443 ± 28	447 ± 46	438 ± 35
				440 ± 31	435 ± 32
800 ppm	434 ± 30	434 ± 38	442 ± 26	446 ± 27	448 ± 27
				448 ± 26	444 ± 27
2400 ppm	429 ± 28	433 ± 28	433 ± 29	436 ± 28	439 ± 27
				437 ± 34	436 ± 29
7200 ppm	379 ± 30**	379 ± 42**	385 ± 29**	385 ± 31**	383 ± 41**
				386 ± 34**	386 ± 40**

Test of Dunnett

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

(HAN260)

BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr16r1j[F344/DuCr1j]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 6

BODY WEIGHT CHANGES
ALL ANIMALS (SUMMARY)

Group Name	Administration week day		week day	
	98-7	102-7	104-7	
Control	434 ± 31	428 ± 41	428 ± 42	
800 ppm	441 ± 29	433 ± 32	426 ± 40	
2400 ppm	435 ± 50	439 ± 82	431 ± 26	
7200 ppm	386 ± 49**	386 ± 61**	387 ± 59**	
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01				
Test of Dunnett				
(HAN260)				
BATS 4				

TABLE C 4

BODY WEIGHT CHANGES: FEMALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]
 UNIT : 8
 REPORT TYPE : A1 I04
 SEX : FEMALE

PAGE : 7

BODY WEIGHT CHANGES
ALL ANIMALS

(SUMMARY)

Group Name	Administration week day					
	0-0	1-7	2-7	3-7	4-7	5-7
Control	100 ± 4	116 ± 5	128 ± 6	137 ± 6	145 ± 7	150 ± 7
800 ppm	100 ± 4	115 ± 4	127 ± 5	135 ± 6	143 ± 6	149 ± 7
2400 ppm	100 ± 4	115 ± 4	128 ± 4	135 ± 5	144 ± 6	149 ± 7
7200 ppm	100 ± 4	110 ± 5**	123 ± 5**	132 ± 6**	138 ± 7**	144 ± 7**

Test of Dunnett

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

(HAN260)

BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]
 UNIT : 8
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 8

BODY WEIGHT CHANGES
(SUMMARY)
ALL ANIMALS

Group Name	Administration week day						
	7-7	8-7	9-7	10-7	11-7	12-7	13-7
Control	160 ± 8	164 ± 8	167 ± 9	171 ± 9	173 ± 10	177 ± 10	178 ± 10
800 ppm	158 ± 8	162 ± 8	165 ± 8	168 ± 8	172 ± 9	176 ± 9	177 ± 9
2400 ppm	159 ± 7	163 ± 8	166 ± 8	170 ± 9	173 ± 9	176 ± 9	178 ± 10
7200 ppm	152 ± 8**	156 ± 9**	159 ± 9**	162 ± 9**	165 ± 10**	167 ± 9**	169 ± 10**

Test of Dunnett

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

(HAN260)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 9

Group Name	Administration week-day					BODY WEIGHT CHANGES ALL ANIMALS	(SUMMARY)
	14-7	18-7	22-7	26-7	30-7	34-7	38-7
Control	180 ± 10	186 ± 10	191 ± 11	196 ± 11	202 ± 13	207 ± 12	210 ± 13
800 ppm	179 ± 9	187 ± 10	192 ± 10	197 ± 10	203 ± 11	210 ± 13	213 ± 12
2400 ppm	180 ± 10	188 ± 10	193 ± 11	199 ± 11	205 ± 12	210 ± 12	213 ± 13
7200 ppm	170 ± 10**	176 ± 10**	180 ± 10**	185 ± 11**	189 ± 10**	192 ± 12**	195 ± 12**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 10

Group Name	Administration week day						BODY WEIGHT CHANGES ALL ANIMALS		(SUMMARY)	
	42-7	46-7	50-7	54-7	58-7	62-7				
Control	215 ± 13	218 ± 14	224 ± 15	227 ± 15	231 ± 15	238 ± 18	244 ± 20			
800 ppm	218 ± 13	221 ± 14	226 ± 15	230 ± 16	234 ± 17	241 ± 18	247 ± 20			
2400 ppm	219 ± 14	222 ± 14	226 ± 14	230 ± 15	234 ± 16	243 ± 18	249 ± 18			
7200 ppm	199 ± 12**	201 ± 13**	203 ± 15**	207 ± 15**	209 ± 16**	212 ± 18**	217 ± 19**			

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(HAN260)

BAIS 4

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr10Cr11[F344/DuCr11]

UNIT : g

REPORT TYPE : A1 104

SEX : FEMALE

BODY WEIGHT CHANGES

ALL ANIMALS

(SUMMARY)

PAGE : 11

Group Name	Administration week day						
	70-7	74-7	78-7	82-7	86-7	90-7	94-7
Control	250 ± 20	255 ± 21	261 ± 21	265 ± 22	267 ± 25	273 ± 26	278 ± 27
800 ppm	253 ± 22	258 ± 23	264 ± 23	270 ± 23	273 ± 24	280 ± 24	284 ± 23
2400 ppm	254 ± 21	259 ± 22	264 ± 26	270 ± 30	275 ± 29	274 ± 28	281 ± 26
7200 ppm	219 ± 20**	222 ± 23**	223 ± 24**	224 ± 26**	227 ± 25**	232 ± 23**	230 ± 23**

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01

Test of Dunnett

(HAN260)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10x1₁[F344/DuCr1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
 ALL ANIMALS

PAGE : 12

Group Name	Administration week day			
	98-7	102-7	104-7	
Control	279 ± 29	280 ± 31	280 ± 31	
800 ppm	284 ± 21	285 ± 24	281 ± 29	
2400 ppm	283 ± 28	284 ± 28	283 ± 30	
7200 ppm	227 ± 22**	222 ± 27**	221 ± 25**	
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01				
Test of Dunnett				
(HAN260)				
BAIS 4				

TABLE D 1

FOOD CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS: MALE

Week-Day on Study	Control			800 ppm			2400 ppm			7200 ppm		
	Av. FC.	No. of Surviv. <50>	Av. FC.	% of cont. <50>	No. of Surviv.	Av. FC.	% of cont. <50>	No. of Surviv.	Av. FC.	% of cont. <50>	No. of Surviv.	
1-7	13.3 (50)	50/50	13.3 (50)	100	50/50	13.4 (50)	101	50/50	11.8 (50)	89	50/50	
2-7	15.0 (50)	50/50	15.1 (50)	101	50/50	14.7 (50)	98	50/50	13.6 (50)	91	50/50	
3-7	15.7 (50)	50/50	15.5 (50)	99	50/50	15.5 (50)	99	50/50	14.2 (50)	90	50/50	
4-7	16.0 (50)	50/50	15.7 (50)	98	50/50	15.6 (50)	98	50/50	14.4 (50)	90	50/50	
5-7	15.6 (50)	50/50	15.6 (50)	100	50/50	15.6 (50)	100	50/50	14.5 (50)	93	50/50	
6-7	15.1 (50)	50/50	15.1 (50)	100	50/50	15.2 (50)	101	50/50	14.2 (50)	94	50/50	
7-7	14.9 (50)	50/50	15.0 (50)	101	50/50	14.9 (50)	100	50/50	14.0 (50)	94	50/50	
8-7	15.4 (50)	50/50	15.7 (50)	102	50/50	15.3 (50)	99	50/50	14.1 (50)	92	50/50	
9-7	14.9 (50)	50/50	15.4 (50)	103	50/50	15.0 (50)	101	50/50	13.6 (50)	91	50/50	
10-7	15.1 (50)	50/50	15.4 (50)	102	50/50	15.5 (50)	103	50/50	14.0 (50)	93	50/50	
11-7	14.4 (50)	50/50	14.7 (50)	102	50/50	14.7 (50)	102	50/50	13.6 (50)	94	50/50	
12-7	14.5 (50)	50/50	14.7 (50)	101	50/50	14.7 (50)	101	50/50	13.6 (50)	94	50/50	
13-7	14.5 (50)	50/50	14.6 (50)	101	50/50	14.4 (50)	99	50/50	13.4 (50)	92	50/50	
14-7	14.7 (50)	50/50	14.7 (50)	100	50/50	14.6 (50)	99	50/50	13.6 (50)	93	50/50	
18-7	14.5 (50)	50/50	14.6 (50)	101	50/50	14.3 (50)	99	50/50	13.2 (50)	91	50/50	
22-7	14.8 (49)	50/50	14.8 (50)	100	50/50	14.8 (50)	100	50/50	13.5 (50)	91	50/50	
26-7	15.0 (50)	50/50	15.1 (50)	101	50/50	14.8 (50)	99	50/50	13.3 (50)	89	50/50	
30-7	14.8 (50)	50/50	14.8 (50)	100	50/50	14.6 (50)	99	50/50	13.3 (50)	90	50/50	
34-7	15.0 (50)	50/50	15.1 (49)	101	49/50	14.9 (50)	99	50/50	13.6 (50)	91	50/50	
38-7	15.3 (50)	50/50	15.3 (49)	100	49/50	15.2 (50)	99	50/50	13.7 (50)	90	50/50	
42-7	15.4 (50)	50/50	15.5 (49)	101	49/50	15.3 (50)	99	50/50	13.9 (50)	90	50/50	
46-7	15.8 (49)	49/50	15.8 (49)	100	49/50	15.5 (50)	98	50/50	14.2 (50)	90	50/50	
50-7	16.1 (49)	49/50	15.9 (49)	99	49/50	15.7 (50)	98	50/50	14.1 (50)	88	50/50	
54-7	15.6 (49)	49/50	15.7 (49)	101	49/50	15.4 (50)	99	50/50	14.1 (50)	90	50/50	
58-7	15.8 (49)	49/50	15.9 (49)	101	49/50	15.6 (50)	99	50/50	14.2 (50)	90	50/50	
62-7	15.9 (48)	48/50	15.8 (49)	99	49/50	15.3 (50)	96	50/50	14.2 (50)	89	50/50	
66-7	16.2 (48)	48/50	16.1 (49)	99	49/50	15.8 (50)	98	50/50	14.8 (50)	91	50/50	
70-7	16.4 (47)	47/50	15.8 (49)	96	49/50	15.8 (50)	96	50/50	14.8 (50)	90	50/50	
74-7	16.2 (47)	47/50	15.9 (49)	98	49/50	15.9 (50)	98	50/50	14.6 (50)	90	50/50	
78-7	16.7 (47)	47/50	16.4 (47)	98	47/50	16.0 (50)	96	50/50	14.6 (48)	87	48/50	
82-7	16.4 (47)	47/50	16.2 (47)	99	47/50	15.8 (47)	96	47/50	14.4 (48)	88	48/50	
86-7	16.5 (46)	46/50	16.3 (47)	99	47/50	15.8 (47)	96	47/50	14.4 (48)	87	48/50	
90-7	16.2 (45)	45/50	16.1 (47)	99	47/50	15.6 (45)	96	45/50	14.3 (48)	88	48/50	
94-7	16.6 (44)	44/50	15.8 (47)	95	47/50	15.9 (42)	96	42/50	14.6 (45)	88	45/50	
98-7	16.2 (41)	42/50	15.9 (46)	98	46/50	15.5 (42)	96	42/50	14.7 (44)	91	44/50	
102-7	15.6 (41)	41/50	15.1 (46)	97	46/50	15.2 (39)	97	40/50	14.3 (41)	92	41/50	
104-7	15.6 (39)	40/50	15.1 (45)	97	45/50	15.5 (38)	99	38/50	14.3 (40)	92	40/50	

TABLE D 2

FOOD CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS: FEMALE

STUDY NO. : 0641
 ANIMAL : RAT F344/duCr101j[F344/duCr1j]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

PAGE : 2

Week-Day on Study	Control			800 ppm			2400 ppm			7200 ppm		
	Av.FC.	No. of Surviv. <50>	Av.FC.	% of cont. <50>	No. of Surviv.	Av.FC.	% of cont. <50>	No. of Surviv.	Av.FC.	% of cont. <50>	No. of Surviv.	
1-7	10.5 (50)	50/50	10.6 (50)	101	50/50	10.4 (50)	99	50/50	9.1 (50)	87	50/50	
2-7	10.7 (50)	50/50	10.7 (50)	100	50/50	10.6 (50)	99	50/50	10.0 (49)	93	50/50	
3-7	10.5 (50)	50/50	10.5 (50)	100	50/50	10.3 (50)	98	50/50	9.8 (50)	93	50/50	
4-7	10.6 (50)	50/50	10.6 (50)	100	50/50	10.5 (50)	99	50/50	9.6 (50)	91	50/50	
5-7	10.3 (50)	50/50	10.3 (50)	100	50/50	10.2 (50)	99	50/50	9.4 (50)	91	50/50	
6-7	10.1 (50)	50/50	10.0 (50)	99	50/50	9.9 (50)	98	50/50	9.2 (50)	91	50/50	
7-7	10.0 (50)	50/50	10.0 (50)	100	50/50	9.9 (50)	99	50/50	9.2 (50)	92	50/50	
8-7	10.1 (50)	50/50	10.1 (50)	100	50/50	9.9 (50)	98	50/50	9.2 (50)	91	50/50	
9-7	9.9 (50)	50/50	9.9 (50)	100	50/50	9.8 (50)	100	50/50	9.0 (50)	91	50/50	
10-7	10.0 (50)	50/50	10.0 (50)	100	50/50	9.8 (50)	98	50/50	9.1 (50)	91	50/50	
11-7	9.9 (50)	50/50	10.0 (50)	101	50/50	9.9 (50)	100	50/50	9.0 (50)	91	50/50	
12-7	10.1 (50)	50/50	10.2 (50)	101	50/50	10.0 (50)	99	50/50	9.1 (50)	90	50/50	
13-7	9.9 (50)	50/50	10.1 (50)	102	50/50	9.9 (50)	100	50/50	9.0 (50)	91	50/50	
14-7	10.1 (50)	50/50	10.4 (50)	103	50/50	10.1 (50)	100	50/50	9.2 (50)	91	50/50	
18-7	9.9 (50)	50/50	10.2 (50)	103	50/50	10.0 (50)	101	50/50	9.0 (50)	91	50/50	
22-7	10.3 (50)	50/50	10.4 (50)	101	50/50	10.2 (50)	99	50/50	9.2 (50)	89	50/50	
26-7	9.9 (50)	50/50	10.1 (50)	102	50/50	10.0 (50)	101	50/50	9.1 (50)	92	50/50	
30-7	10.1 (50)	50/50	10.3 (50)	102	50/50	10.3 (50)	102	50/50	9.2 (50)	91	50/50	
34-7	10.3 (50)	50/50	10.4 (50)	101	50/50	10.3 (50)	100	50/50	9.2 (50)	89	50/50	
38-7	10.3 (50)	50/50	10.4 (50)	101	50/50	10.4 (50)	101	50/50	9.4 (49)	91	49/50	
42-7	10.5 (50)	50/50	10.7 (50)	102	50/50	10.6 (50)	101	50/50	9.8 (49)	93	49/50	
46-7	10.6 (50)	50/50	10.8 (50)	102	50/50	10.7 (50)	101	50/50	9.7 (49)	92	49/50	
50-7	10.8 (50)	50/50	11.0 (50)	102	50/50	10.9 (50)	101	50/50	9.9 (49)	92	49/50	
54-7	11.0 (50)	50/50	11.1 (50)	101	50/50	11.3 (50)	103	50/50	10.1 (49)	92	49/50	
58-7	11.1 (50)	50/50	11.0 (50)	99	50/50	10.9 (50)	98	50/50	10.0 (49)	90	49/50	
62-7	11.3 (50)	50/50	11.5 (50)	102	50/50	11.3 (50)	100	50/50	10.1 (49)	89	49/50	
66-7	11.5 (50)	50/50	11.4 (49)	99	49/50	11.4 (50)	99	50/50	10.3 (47)	90	47/50	
70-7	11.7 (50)	50/50	11.9 (49)	102	49/50	11.3 (50)	97	50/50	10.6 (47)	91	47/50	
74-7	11.6 (50)	50/50	11.8 (49)	102	49/50	11.5 (50)	99	50/50	10.6 (46)	91	46/50	
78-7	12.0 (50)	50/50	12.2 (48)	102	48/50	11.9 (50)	99	50/50	10.5 (44)	88	44/50	
82-7	11.8 (49)	49/50	12.0 (46)	102	46/50	11.9 (50)	101	50/50	10.4 (44)	88	44/50	
86-7	11.5 (49)	49/50	11.6 (44)	101	44/50	11.9 (50)	103	50/50	10.4 (42)	90	42/50	
90-7	11.8 (48)	48/50	12.1 (43)	103	43/50	11.6 (49)	98	49/50	10.8 (38)	92	38/50	
94-7	12.1 (46)	46/50	12.7 (43)	105	43/50	12.4 (48)	102	48/50	10.5 (38)	87	38/50	
98-7	12.1 (44)	44/50	12.3 (42)	102	42/50	12.0 (46)	99	46/50	10.8 (36)	89	36/50	
102-7	12.1 (40)	40/50	12.1 (39)	100	39/50	11.8 (41)	98	41/50	10.5 (35)	87	35/50	
104-7	11.8 (38)	38/50	11.7 (38)	99	38/50	11.7 (42)	99	42/50	10.5 (33)	89	33/50	

< >:No. of effective animals, () :No. of measured animals Av. FC. : g

(B10040)

BAIS 4

TABLE D 3

FOOD CONSUMPTION CHANGES: MALE

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]

UNIT : g

REPORT TYPE : A1 104

SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

PAGE : 1

Group Name	Administration week day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	13.3± 0.8	15.0± 0.9	15.7± 1.1	16.0± 0.9	15.6± 0.8	15.1± 1.0	14.9± 1.0
800 ppm	13.3± 0.8	15.1± 1.3	15.5± 1.2	15.7± 1.1	15.6± 1.0	15.1± 1.0	15.0± 1.0
2400 ppm	13.4± 0.8	14.7± 1.0	15.5± 1.0	15.6± 1.1	15.6± 1.0	15.2± 1.1	14.9± 1.1
7200 ppm	11.8± 0.7**	13.6± 1.0**	14.2± 1.1**	14.4± 1.0**	14.5± 0.8**	14.2± 0.9**	14.0± 0.9**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01							
Test of Dunnett							
(HAN260)							BATS 4

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	15.4± 1.1	14.9± 1.1	15.1± 1.2	14.4± 1.1	14.5± 1.0	14.5± 0.9	14.7± 0.9
800 ppm	15.7± 1.2	15.4± 1.2	15.4± 1.2	14.7± 1.0	14.7± 1.0	14.6± 0.9	14.7± 0.9
2400 ppm	15.3± 1.1	15.0± 1.1	15.5± 1.0	14.7± 1.0	14.7± 0.9	14.4± 0.9	14.6± 1.0
7200 ppm	14.1± 1.0**	13.6± 1.0**	14.0± 1.0**	13.6± 1.0**	13.6± 1.0**	13.4± 1.0**	13.6± 0.9**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01							Test of Dunnett
(HAN260)							BAIS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCrIOr1j[F344/DuCr1j]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

PAGE : 3

Group Name	Administration week-day(effective)				
	18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)
Control	14.5± 0.9	14.8± 1.0	15.0± 0.9	14.8± 0.9	15.0± 1.1
					15.3± 1.0
					15.4± 1.0
800 ppm	14.6± 0.8	14.8± 1.0	15.1± 1.0	14.8± 0.9	15.1± 0.9
					15.3± 0.9
					15.5± 0.9
2400 ppm	14.3± 1.1	14.8± 1.0	14.8± 1.1	14.6± 0.9	14.9± 1.0
					15.2± 0.9
					15.3± 1.1
7200 ppm	13.2± 1.0**	13.5± 1.0**	13.3± 1.1**	13.3± 0.9**	13.6± 1.0**
					13.7± 1.0**
					13.9± 1.1**

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260)

BAIS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

PAGE : 4

Group Name	Administration week day(effective)						
	46-7 (7)	50-7 (7)	54-7 (7)	58-7 (7)	62-7 (7)	66-7 (7)	70-7 (7)
Control	15.8 ± 0.9	16.1 ± 0.8	15.6 ± 0.8	15.8 ± 1.3	15.9 ± 0.9	16.2 ± 1.3	16.4 ± 0.9
800 ppm	15.8 ± 1.0	15.9 ± 1.1	15.7 ± 0.9	15.9 ± 0.9	15.8 ± 1.0	16.1 ± 1.0	15.8 ± 2.1*
2400 ppm	15.5 ± 1.1	15.7 ± 1.1*	15.4 ± 1.0	15.6 ± 1.0	15.3 ± 1.0*	15.8 ± 1.0	15.8 ± 1.1*
7200 ppm	14.2 ± 1.0**	14.1 ± 1.6**	14.1 ± 1.1**	14.2 ± 1.2**	14.2 ± 1.1**	14.8 ± 1.1**	14.8 ± 1.1**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260)

BAIS 4

Group Name	Administration week-day(effective)						
	74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	16.2± 1.0	16.7± 1.1	16.4± 1.5	16.5± 1.4	16.2± 1.6	16.6± 2.0	16.2± 1.3
800 ppm	15.9± 1.4	16.4± 1.0	16.2± 1.0	16.3± 0.8	16.1± 1.1	15.8± 2.4	15.9± 1.3
2400 ppm	15.9± 1.1	16.0± 2.4	15.8± 1.3	15.8± 2.2	15.6± 1.6	15.9± 1.3	15.5± 2.2
7200 ppm	14.6± 1.4**	14.6± 1.2**	14.4± 1.2**	14.4± 1.4**	14.3± 1.8**	14.6± 1.2**	14.7± 1.4**
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01							
Test of Dunnett							
(HAN260)							BALS 4

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]

UNIT : g

REPORT TYPE : A1 104

SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)

ALL ANIMALS

PAGE : 6

Group Name	Administration	week day(effective)
	102-7(7)	104-7(7)
Control	15.6± 2.7	15.6± 2.1
800 ppm	15.1± 1.8	15.1± 2.2
2400 ppm	15.2± 1.4	15.5± 1.3
7200 ppm	14.3± 1.6**	14.3± 1.8**
<div>Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01</div> <div>Test of Dunnett</div> <div>(HAN260)</div> <div>BAS 4</div>		

TABLE D 4

FOOD CONSUMPTION CHANGES: FEMALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[T344/DuCr1J]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 7

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	10.5± 0.7	10.7± 0.6	10.5± 0.7	10.6± 0.6	10.3± 0.6	10.1± 0.7	10.0± 0.6
800 ppm	10.6± 0.6	10.7± 0.6	10.5± 0.7	10.6± 0.6	10.3± 0.7	10.0± 0.6	10.0± 0.7
2400 ppm	10.4± 0.5	10.6± 0.6	10.3± 0.5	10.5± 0.7	10.2± 0.8	9.9± 0.6	9.9± 0.7
7200 ppm	9.1± 0.6**	10.0± 0.6**	9.8± 0.6**	9.6± 0.7**	9.4± 0.6**	9.2± 0.7**	9.2± 0.7**
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01							
				Test of Dunnett			
(HAN260)				BAIS 4			

Group Name	Administration week-day(effective)						
	8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	10.1± 0.7	9.9± 0.7	10.0± 0.7	9.9± 0.7	10.1± 0.7	9.9± 0.7	10.1± 0.7
800 ppm	10.1± 0.7	9.9± 0.6	10.0± 0.6	10.0± 0.7	10.2± 0.7	10.1± 0.6	10.4± 0.7
2400 ppm	9.9± 0.7	9.9± 0.7	9.8± 0.7	9.9± 0.7	10.0± 0.7	9.9± 0.7	10.1± 0.6
7200 ppm	9.2± 0.6**	9.0± 0.7**	9.1± 0.7**	9.0± 0.7**	9.1± 0.6**	9.0± 0.6**	9.2± 0.6**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01							Test of Dunnett
(HAN260)							BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

PAGE : 9

Group Name	Administration 18-7 (7)	week-day(effective) 22-7 (7)	26-7 (7)	30-7 (7)	34-7 (7)	38-7 (7)	42-7 (7)
Control	9.9 ± 0.7	10.3 ± 0.6	9.9 ± 0.6	10.1 ± 0.7	10.3 ± 0.5	10.3 ± 0.5	10.5 ± 0.6
800 ppm	10.2 ± 0.6	10.4 ± 0.7	10.1 ± 0.6	10.3 ± 0.6	10.4 ± 0.7	10.4 ± 0.6	10.7 ± 0.8
2400 ppm	10.0 ± 0.7	10.2 ± 0.7	10.0 ± 0.6	10.3 ± 0.6	10.3 ± 0.8	10.4 ± 0.8	10.6 ± 0.7
7200 ppm	9.0 ± 0.6**	9.2 ± 0.5**	9.1 ± 0.6**	9.2 ± 0.5**	9.2 ± 0.5**	9.4 ± 0.6**	9.8 ± 0.8**

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(HAN260)

BALS 4

Group Name	Administration week day(effective)				
	46-7(7)	50-7(7)	54-7(7)	58-7(7)	62-7(7)
Control	10.6± 0.7	10.8± 0.8	11.0± 0.7	11.1± 0.6	11.3± 0.9
800 ppm	10.8± 0.7	11.0± 0.8	11.1± 0.9	11.0± 0.9	11.5± 0.9
2400 ppm	10.7± 0.7	10.9± 0.8	11.3± 2.6	10.9± 0.9	11.3± 0.9
7200 ppm	9.7± 0.8**	9.9± 0.9**	10.1± 0.8**	10.0± 0.7**	10.1± 0.9**
					10.3± 0.8**
					10.6± 0.9**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8
					11.4± 1.0
					11.5± 0.9
					11.7± 1.1
					11.9± 1.1
					11.3± 1.0
					10.6± 0.9**
					10.3± 0.8**
					11.4± 0.8

Group Name	Administration week day(effective)				
	74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)
Control	11.6± 0.8	12.0± 0.9	11.8± 1.0	11.5± 1.1	11.8± 1.1
					12.1± 1.9
					12.1± 1.8
800 ppm	11.8± 1.2	12.2± 1.2	12.0± 1.1	11.6± 1.9	12.1± 1.1
					12.7± 1.5
					12.3± 1.6
2400 ppm	11.5± 0.8	11.9± 1.0	11.9± 1.3	11.9± 2.1	11.6± 1.2
					12.4± 1.0
					12.0± 1.5
7200 ppm	10.6± 1.0**	10.5± 1.2**	10.4± 1.6**	10.4± 1.1**	10.8± 1.1**
					10.5± 1.5**
					10.8± 1.2**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01					Test of Dunnett
(HAN260)					BATS 4

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

PAGE : 12

Group Name	Administration week day(effective) 102-7(7)	104-7(7)
Control	12.1± 1.3	11.8± 1.2
800 ppm	12.1± 1.6	11.7± 1.9
2400 ppm	11.8± 1.1	11.7± 1.0
7200 ppm	10.5± 2.0**	10.5± 1.4**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett		
(HAN260)		
BAIS 4		

TABLE E 1

WATER CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS: MALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCrj]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : MALE

MEAN WATER CONSUMPTION(WC) AND SURVIVAL

PAGE : 1

Week-Day on Study	Control			800 ppm			2400 ppm			7200 ppm		
	Av.WC.	No. of Surviv.	Av.WC.	% of cont.	No. of Surviv.	Av.WC.	% of cont.	No. of Surviv.	Av.WC.	% of cont.	No. of Surviv.	% of cont.
1-7	16.3 (50)	50/50	15.6 (50)	96	50/50	14.6 (50)	90	50/50	13.1 (50)	80	50/50	50/50
2-7	17.5 (50)	50/50	16.9 (50)	97	50/50	15.7 (50)	90	50/50	13.4 (50)	77	50/50	50/50
3-7	18.0 (50)	50/50	17.6 (49)	98	50/50	16.3 (50)	91	50/50	13.0 (49)	72	50/50	50/50
4-7	17.9 (50)	50/50	18.4 (50)	103	50/50	16.2 (50)	91	50/50	12.8 (50)	72	50/50	50/50
5-7	17.8 (49)	50/50	17.7 (50)	99	50/50	16.2 (50)	91	50/50	12.9 (50)	72	50/50	50/50
6-7	17.5 (50)	50/50	17.5 (49)	100	50/50	16.7 (50)	95	50/50	12.6 (50)	72	50/50	50/50
7-7	17.1 (50)	50/50	18.1 (48)	106	50/50	16.5 (50)	96	50/50	12.8 (50)	75	50/50	50/50
8-7	16.8 (50)	50/50	18.7 (47)	111	50/50	16.6 (50)	99	50/50	12.7 (50)	76	50/50	50/50
9-7	17.0 (50)	50/50	18.1 (49)	106	50/50	17.3 (49)	102	50/50	13.1 (50)	77	50/50	50/50
10-7	17.2 (50)	50/50	17.5 (49)	102	50/50	17.2 (49)	100	50/50	13.3 (50)	77	50/50	50/50
11-7	17.2 (50)	50/50	16.8 (50)	98	50/50	16.6 (50)	97	50/50	12.5 (50)	73	50/50	50/50
12-7	17.5 (50)	50/50	17.1 (48)	98	50/50	15.9 (50)	91	50/50	12.0 (50)	69	50/50	50/50
13-7	16.7 (50)	50/50	16.7 (49)	100	50/50	15.4 (49)	92	50/50	11.6 (50)	69	50/50	50/50
14-7	17.1 (50)	50/50	16.8 (49)	98	50/50	15.4 (50)	90	50/50	12.5 (50)	73	50/50	50/50
18-7	16.0 (50)	50/50	16.3 (50)	102	50/50	15.0 (50)	94	50/50	11.3 (50)	71	50/50	50/50
22-7	15.8 (50)	50/50	16.1 (50)	102	50/50	14.9 (50)	94	50/50	11.4 (50)	72	50/50	50/50
26-7	16.1 (50)	50/50	16.5 (50)	102	50/50	15.5 (50)	96	50/50	12.4 (50)	77	50/50	50/50
30-7	15.7 (50)	50/50	16.3 (50)	104	50/50	15.0 (50)	96	50/50	12.5 (50)	80	50/50	50/50
34-7	16.0 (50)	50/50	16.4 (49)	103	49/50	15.2 (50)	95	50/50	12.3 (50)	77	50/50	50/50
38-7	16.1 (50)	50/50	16.1 (49)	100	49/50	15.3 (50)	95	50/50	12.2 (50)	76	50/50	50/50
42-7	16.1 (50)	50/50	16.7 (49)	104	49/50	15.4 (50)	96	50/50	12.6 (50)	78	50/50	50/50
46-7	16.5 (49)	49/50	16.7 (49)	101	49/50	15.6 (50)	95	50/50	13.0 (50)	79	50/50	50/50
50-7	16.4 (49)	49/50	17.1 (49)	101	49/50	15.9 (50)	97	50/50	13.0 (50)	79	50/50	50/50
54-7	16.3 (49)	49/50	16.6 (49)	102	49/50	15.8 (50)	97	50/50	12.9 (50)	79	50/50	50/50
58-7	16.4 (49)	49/50	16.6 (49)	101	49/50	15.8 (50)	96	50/50	13.0 (50)	79	50/50	50/50
62-7	17.0 (48)	48/50	16.9 (49)	99	49/50	15.9 (50)	94	50/50	13.1 (50)	77	50/50	50/50
66-7	16.8 (48)	48/50	16.7 (49)	99	49/50	15.9 (50)	95	50/50	13.6 (50)	81	50/50	50/50
70-7	17.5 (47)	47/50	16.8 (49)	96	49/50	16.1 (50)	92	50/50	14.0 (50)	80	50/50	50/50
74-7	17.5 (47)	47/50	16.7 (49)	95	49/50	16.4 (50)	94	50/50	14.1 (50)	81	50/50	50/50
78-7	18.0 (46)	47/50	17.7 (47)	98	47/50	16.5 (50)	92	50/50	14.9 (48)	83	48/50	50/50
82-7	18.4 (46)	47/50	17.3 (47)	94	47/50	16.4 (47)	89	47/50	14.2 (48)	77	48/50	50/50
86-7	18.5 (44)	46/50	18.0 (47)	97	47/50	16.5 (47)	89	47/50	13.9 (48)	75	48/50	50/50
90-7	18.4 (42)	44/50	17.7 (47)	96	47/50	16.9 (45)	92	45/50	14.4 (48)	78	48/50	50/50
94-7	18.3 (39)	44/50	18.5 (47)	101	47/50	17.2 (41)	94	42/50	14.7 (45)	80	45/50	50/50
98-7	18.7 (37)	42/50	18.8 (46)	101	46/50	18.2 (41)	97	42/50	15.1 (44)	81	44/50	50/50
102-7	19.0 (37)	41/50	19.2 (45)	101	46/50	18.4 (38)	97	40/50	15.0 (41)	79	41/50	50/50
104-7	20.0 (36)	40/50	18.7 (41)	94	45/50	18.8 (37)	94	38/50	15.3 (40)	77	40/50	50/50

< >:No. of effective animals, () :No. of measured animals

Av. WC : g

(B10040)

BALS 4

TABLE E 2

WATER CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS: FEMALE

STUDY NO. : 0641
ANIMAL : RAT F344/DuCrjCrj[F344/DuCrj]
UNIT : g
REPORT TYPE : AI 104
SEX : FEMALE

MEAN WATER CONSUMPTION(WC) AND SURVIVAL

PAGE : 2

Week-Day on Study	Control			800 ppm			2400 ppm			7200 ppm		
	Av. WC.	No. of Surviv. <50>	Av. WC.	% of cont. <50>	No. of Surviv.	Av. WC.	% of cont. <50>	No. of Surviv.	Av. WC.	% of cont. <50>	No. of Surviv.	
1-7	15.4 (49)	50/50	15.7 (48)	102	50/50	13.9 (50)	90	50/50	10.8 (50)	70	50/50	
2-7	15.9 (49)	50/50	18.0 (48)	113	50/50	14.1 (50)	89	50/50	10.3 (50)	65	50/50	
3-7	16.0 (47)	50/50	15.9 (38)	99	50/50	14.5 (44)	91	50/50	10.7 (50)	67	50/50	
4-7	15.6 (45)	50/50	16.7 (36)	107	50/50	15.6 (47)	100	50/50	10.3 (50)	66	50/50	
5-7	18.0 (48)	50/50	18.0 (39)	100	50/50	16.3 (48)	91	50/50	10.1 (50)	56	50/50	
6-7	16.1 (44)	50/50	17.3 (36)	107	50/50	16.2 (44)	101	50/50	9.9 (50)	61	50/50	
7-7	15.9 (44)	50/50	18.0 (31)	113	50/50	15.5 (37)	97	50/50	10.6 (49)	67	50/50	
8-7	16.6 (43)	50/50	16.5 (30)	99	50/50	15.0 (38)	90	50/50	10.0 (50)	60	50/50	
9-7	16.5 (47)	50/50	18.5 (33)	112	50/50	16.1 (44)	98	50/50	9.6 (50)	58	50/50	
10-7	16.4 (47)	50/50	17.6 (39)	107	50/50	14.6 (41)	89	50/50	9.5 (50)	58	50/50	
11-7	16.5 (42)	50/50	18.2 (40)	110	50/50	15.6 (41)	95	50/50	9.4 (49)	57	50/50	
12-7	15.9 (43)	50/50	18.7 (34)	118	50/50	14.6 (43)	92	50/50	9.6 (50)	60	50/50	
13-7	16.4 (46)	50/50	18.4 (34)	112	50/50	16.0 (39)	98	50/50	9.8 (50)	60	50/50	
14-7	16.3 (43)	50/50	18.0 (29)	110	50/50	15.2 (39)	93	50/50	9.7 (49)	60	50/50	
18-7	17.2 (46)	50/50	16.7 (27)	97	50/50	15.4 (39)	90	50/50	10.4 (50)	60	50/50	
22-7	16.8 (44)	50/50	18.6 (42)	111	50/50	16.4 (43)	98	50/50	10.3 (50)	61	50/50	
26-7	17.0 (47)	50/50	18.5 (40)	109	50/50	16.5 (44)	97	50/50	10.7 (48)	63	50/50	
30-7	16.5 (47)	50/50	18.4 (40)	112	50/50	15.6 (38)	95	50/50	10.5 (50)	64	50/50	
34-7	16.7 (48)	50/50	17.3 (44)	104	50/50	15.1 (43)	90	50/50	10.5 (48)	63	50/50	
38-7	16.2 (47)	50/50	17.9 (45)	110	50/50	15.4 (43)	95	50/50	10.8 (49)	67	49/50	
42-7	15.9 (49)	50/50	18.3 (44)	115	50/50	16.0 (44)	101	50/50	11.1 (49)	70	49/50	
46-7	15.7 (49)	50/50	16.0 (45)	102	50/50	16.7 (46)	106	50/50	10.8 (48)	69	49/50	
50-7	15.1 (49)	50/50	16.6 (44)	110	50/50	17.0 (43)	113	50/50	11.8 (49)	78	49/50	
54-7	15.3 (49)	50/50	15.5 (45)	101	50/50	15.2 (44)	99	50/50	11.4 (48)	75	49/50	
58-7	14.7 (50)	50/50	15.2 (49)	103	50/50	14.9 (47)	101	50/50	11.1 (49)	76	49/50	
62-7	14.7 (50)	50/50	16.4 (49)	112	50/50	14.3 (47)	97	50/50	11.3 (48)	77	49/50	
66-7	14.7 (49)	50/50	16.6 (46)	113	49/50	14.2 (47)	97	50/50	11.2 (47)	76	47/50	
70-7	14.7 (50)	50/50	15.5 (47)	105	49/50	14.1 (47)	96	50/50	12.4 (47)	84	47/50	
74-7	14.4 (50)	50/50	15.5 (47)	108	49/50	14.8 (48)	103	50/50	12.4 (46)	86	46/50	
78-7	14.6 (50)	50/50	16.3 (46)	112	48/50	14.5 (48)	99	50/50	12.5 (44)	86	44/50	
82-7	14.3 (48)	49/50	15.6 (46)	109	46/50	14.3 (49)	100	50/50	12.9 (43)	90	44/50	
86-7	15.0 (47)	49/50	15.8 (42)	105	44/50	15.4 (48)	103	50/50	13.2 (42)	88	42/50	
90-7	14.9 (46)	48/50	15.3 (43)	103	43/50	14.4 (49)	97	49/50	13.8 (38)	93	38/50	
94-7	15.5 (45)	46/50	15.6 (41)	101	43/50	14.8 (47)	95	48/50	15.3 (37)	99	38/50	
98-7	16.1 (44)	44/50	16.4 (41)	102	42/50	15.3 (45)	95	46/50	16.8 (36)	104	36/50	
102-7	16.7 (40)	40/50	16.4 (34)	98	39/50	16.1 (44)	98	41/50	17.1 (35)	102	35/50	
104-7	16.8 (38)	38/50	16.4 (36)	98	38/50	15.9 (42)	95	42/50	18.4 (31)	110	33/50	

< >:No. of effective animals, () :No. of measured animals Av. WC. : g

(B10040)

BALS 4

TABLE E 3

WATER CONSUMPTION CHANGES: MALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 1

WATER CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	1-7(3)	2-7(3)	3-7(3)	4-7(3)	5-7(3)	6-7(3)	7-7(3)
Control	16.3± 1.6	17.5± 1.4	18.0± 1.8	17.9± 1.5	17.8± 1.7	17.5± 1.9	17.1± 1.8
800 ppm	15.6± 1.0	16.9± 1.8*	17.6± 2.3	18.4± 3.9	17.7± 2.5	17.5± 3.0	18.1± 2.4*
2400 ppm	14.6± 1.0**	15.7± 1.2**	16.3± 1.2**	16.2± 1.6**	16.2± 1.6**	16.7± 3.3**	16.5± 2.3*
7200 ppm	13.1± 4.5**	13.4± 2.1**	13.0± 1.2**	12.8± 1.0**	12.9± 1.1**	12.6± 0.9**	12.8± 1.1**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BALS 4

Group Name	Administration week day(effective)						
	8-7(3)	9-7(3)	10-7(3)	11-7(3)	12-7(3)	13-7(3)	14-7(3)
Control	16.8± 1.4	17.0± 1.8	17.2± 2.0	17.2± 2.3	17.5± 2.3	16.7± 1.8	17.1± 2.5
800 ppm	18.7± 2.1**	18.1± 2.1**	17.5± 2.7	16.8± 2.0	17.1± 3.0	16.7± 2.6	16.8± 3.0
2400 ppm	16.6± 2.0	17.3± 2.1	17.2± 1.4	16.6± 2.4	15.9± 2.5**	15.4± 1.5**	15.4± 2.2**
7200 ppm	12.7± 1.1**	13.1± 1.3**	13.3± 1.2**	12.5± 1.1**	12.0± 1.2**	11.6± 0.9**	12.5± 2.2**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01							Test of Dunnett
(HAN260)							BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 3

WATER CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 18-7(3)	week-day(effective) 22-7(3)	26-7(3)	30-7(3)	34-7(3)	38-7(3)	42-7(3)
Control	16.0 ± 1.4	15.8 ± 1.4	16.1 ± 1.0	15.7 ± 1.2	16.0 ± 1.3	16.1 ± 1.3	16.1 ± 1.3
800 ppm	16.3 ± 2.1	16.1 ± 2.4	16.5 ± 1.7	16.3 ± 1.7	16.4 ± 1.5	16.1 ± 1.4	16.7 ± 1.4**
2400 ppm	15.0 ± 1.4**	14.9 ± 1.5**	15.5 ± 1.2**	15.0 ± 1.1**	15.2 ± 0.9**	15.3 ± 1.0**	15.4 ± 0.9**
7200 ppm	11.3 ± 1.1**	11.4 ± 0.9**	12.4 ± 1.1**	12.5 ± 1.1**	12.3 ± 0.9**	12.2 ± 0.9**	12.6 ± 1.1**
Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$							
Test of Dunnett							
(HAN260)							BA1S 4

WATER CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration 46-7 (3)	week day(effective) 50-7 (3)	54-7 (3)	58-7 (3)	62-7 (3)	66-7 (3)	70-7 (3)
Control	16.5 ± 1.2	16.4 ± 1.2	16.3 ± 1.0	16.4 ± 1.5	17.0 ± 1.3	16.8 ± 2.0	17.5 ± 2.0
800 ppm	16.7 ± 1.4	17.1 ± 2.7*	16.6 ± 1.3	16.6 ± 1.2	16.9 ± 1.4	16.7 ± 1.4	16.8 ± 2.1
2400 ppm	15.6 ± 1.3**	15.9 ± 1.0	15.8 ± 1.2	15.8 ± 1.0**	15.9 ± 1.3**	15.9 ± 1.1**	16.1 ± 1.3**
7200 ppm	13.0 ± 1.0**	13.0 ± 1.2**	12.9 ± 1.3**	13.0 ± 1.2**	13.1 ± 1.3**	13.6 ± 1.5**	14.0 ± 1.5**

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10x1j[F344/DuCr1j]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : MALE

PAGE : 5

WATER CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week day(effective)				
	74-7(3)	78-7(3)	82-7(3)	86-7(3)	90-7(3)
Control	17.5± 2.3	18.0± 2.3	18.4± 3.0	18.5± 3.3	18.4± 3.3
800 ppm	16.7± 2.0	17.7± 1.5	17.3± 1.5	18.0± 1.9	17.7± 2.2
2400 ppm	16.4± 1.3*	16.5± 2.4**	16.4± 1.8**	16.5± 2.1**	16.9± 2.2
7200 ppm	14.1± 1.4**	14.9± 1.7**	14.2± 1.5**	13.9± 2.0**	14.4± 2.2**
				14.7± 2.0**	15.1± 2.8**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260)

BALS 4

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr1Grlj[F344/DuCr1j]

UNIT : g

REPORT TYPE : AI 104

SEX : MALE

WATER CONSUMPTION CHANGES (SUMMARY)

ALL ANIMALS

PAGE : 6

Group Name	Administration week-day(effective)	
	102-7(3)	104-7(3)
Control	19.0± 3.7	20.0± 4.3
800 ppm	19.2± 3.4	18.7± 3.9
2400 ppm	18.4± 2.9	18.8± 3.4
7200 ppm	15.0± 2.9**	15.3± 2.8**
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01		
Test of Dunnett		
(HAN260)		
BALS 4		

TABLE E 4

WATER CONSUMPTION CHANGES: FEMALE

Group Name	Administration week day(effective)						
	1-7(3)	2-7(3)	3-7(3)	4-7(3)	5-7(3)	6-7(3)	7-7(3)
Control	15.4± 3.4	15.9± 4.2	16.0± 2.7	15.6± 2.7	18.0± 7.6	16.1± 4.0	15.9± 4.1
800 ppm	15.7± 4.2	18.0± 7.6	15.9± 3.4	16.7± 4.6	18.0± 6.9	17.3± 5.4	18.0± 5.3
2400 ppm	13.9± 4.0**	14.1± 4.5**	14.5± 4.4**	15.6± 4.1	16.3± 6.5*	16.2± 5.9*	15.5± 4.7
7200 ppm	10.8± 1.0**	10.3± 0.8**	10.7± 2.6**	10.3± 2.3**	10.1± 1.2**	9.9± 1.0**	10.6± 2.3**
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01							Test of Dunnett
(HAN260)							BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 8

WATER CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week-day(effective)						
	8-7(3)	9-7(3)	10-7(3)	11-7(3)	12-7(3)	13-7(3)	14-7(3)
Control	16.6± 4.8	16.5± 7.1	16.4± 4.4	16.5± 4.6	15.9± 3.8	16.4± 4.5	16.3± 4.8
800 ppm	16.5± 4.9	18.5± 7.4	17.6± 5.8	18.2± 5.1	18.7± 5.5	18.4± 5.3	18.0± 5.0
2400 ppm	15.0± 4.1	16.1± 5.2	14.6± 3.9*	15.6± 4.9	14.6± 4.3*	16.0± 5.6	15.2± 4.8
7200 ppm	10.0± 3.2**	9.6± 1.3**	9.5± 2.0**	9.4± 1.5**	9.6± 3.0**	9.8± 2.6**	9.7± 3.3**
Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett							
(HAN260)							BAIS 4

SEX : FEMALE

WATER CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

PAGE : 9

Group Name	Administration week-day(effective)					
	18-7 (3)	22-7 (3)	26-7 (3)	30-7 (3)	34-7 (3)	42-7 (3)
Control	17.2 ± 4.8	16.8 ± 4.8	17.0 ± 4.7	16.5 ± 4.6	16.7 ± 4.0	15.9 ± 3.5
800 ppm	16.7 ± 4.9	18.6 ± 5.4	18.5 ± 5.2	18.4 ± 4.7	17.3 ± 4.6	18.3 ± 4.8*
2400 ppm	15.4 ± 4.3	16.4 ± 5.4	16.5 ± 5.1	15.6 ± 4.2	15.1 ± 3.6*	16.0 ± 4.9
7200 ppm	10.4 ± 3.0**	10.3 ± 3.8**	10.7 ± 3.0**	10.5 ± 2.5**	10.5 ± 2.2**	11.1 ± 2.8**

Test of Dunnett

***: P < 0.01

$$*: P \leq 0.05$$

Significant difference ;

(HAN260)

BAIS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 10

WATER CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week day(effective)						
	46-7(3)	50-7(3)	54-7(3)	58-7(3)	62-7(3)	66-7(3)	70-7(3)
Control	15.7 ± 3.6	15.1 ± 3.2	15.3 ± 4.0	14.7 ± 2.9	14.7 ± 2.8	14.7 ± 2.8	14.7 ± 2.8
800 ppm	16.0 ± 3.3	16.6 ± 4.0	15.5 ± 3.7	15.2 ± 3.6	16.4 ± 4.4	16.6 ± 4.6	15.5 ± 3.2
2400 ppm	16.7 ± 4.7	17.0 ± 5.5	15.2 ± 4.6	14.9 ± 4.5	14.3 ± 4.0	14.2 ± 3.5	14.1 ± 3.4
7200 ppm	10.8 ± 1.9**	11.8 ± 3.6**	11.4 ± 3.1**	11.1 ± 2.7**	11.3 ± 2.5**	11.2 ± 2.3**	12.4 ± 2.8**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10x1j[F344/DuCr1j]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

PAGE : 11

WATER CONSUMPTION CHANGES (SUMMARY)
 ALL ANIMALS

Group Name	Administration week day(effective)						
	74-7(3)	78-7(3)	82-7(3)	86-7(3)	90-7(3)	94-7(3)	98-7(3)
Control	14.4± 3.0	14.6± 3.0	14.3± 2.1	15.0± 2.5	14.9± 2.5	15.5± 3.8	16.1± 4.4
800 ppm	15.5± 4.1	16.3± 4.4	15.6± 4.2	15.8± 5.5	15.3± 3.6	15.6± 3.6	16.4± 3.9
2400 ppm	14.8± 3.5	14.5± 3.3	14.3± 3.3	15.4± 5.8	14.4± 4.3*	14.8± 3.5	15.3± 3.8
7200 ppm	12.4± 2.9**	12.5± 3.4**	12.9± 3.3*	13.2± 2.4**	13.8± 2.8*	15.3± 2.6	16.8± 3.7

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett

(HAN260)

BATS 4

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
UNIT : g
REPORT TYPE : AI 104
SEX : FEMALE

WATER CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

PAGE : 12

Group Name	Administration	week-day(effective)	
	102-7 (3)	104-7 (3)	
Control	16.7± 3.8	16.8± 3.9	
800 ppm	16.4± 3.8	16.4+ 3.8	
2400 ppm	16.4± 4.9	15.9± 3.6	
7200 ppm	17.1± 3.9	18.4± 3.3	
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01			
Test of Dunnett			
(HAN260)			
BAIS 4			

TABLE F 1

CHEMICAL INTAKE CHANGES: MALE

Group Name	Administration (weeks)						
	1	2	3	4	5	6	7
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0
800 ppm	84 ± 4	76 ± 6	69 ± 8	66 ± 14	59 ± 9	56 ± 11	55 ± 7
2400 ppm	235 ± 10	210 ± 11	192 ± 11	172 ± 14	162 ± 12	158 ± 27	150 ± 17
7200 ppm	667 ± 243	567 ± 77	483 ± 31	432 ± 24	405 ± 25	375 ± 21	365 ± 24

(HAN300)

BATS 4

Group Name	Administration (weeks)													
	8	9	10	11	12	13	14							
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0							
800 ppm	55 ± 6	52 ± 6	48 ± 8	45 ± 6	45 ± 10	43 ± 7	43 ± 9							
2400 ppm	146 ± 14	147 ± 15	143 ± 10	134 ± 17	125 ± 16	119 ± 8	117 ± 14							
7200 ppm	352 ± 26	353 ± 28	349 ± 27	323 ± 21	304 ± 24	289 ± 21	306 ± 53							

(HAN300)

BALS 4

Group Name	Administration (weeks)									
	18	22	26	30	34	38	42			
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0	0 ± 0	0
800 ppm	39 ± 5	37 ± 6	37 ± 4	35 ± 4	34 ± 3	33 ± 2	33 ± 3	3	33 ± 3	3
2400 ppm	108 ± 7	102 ± 8	103 ± 6	97 ± 6	96 ± 4	95 ± 5	94 ± 4	4	94 ± 5	4
7200 ppm	264 ± 22	258 ± 18	273 ± 23	267 ± 22	257 ± 15	250 ± 16	256 ± 21	21	256 ± 21	21

(HAN300)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1i[F344/DuCr1i]
 UNIT : mg/kg/d a y
 REPORT TYPE : AI 104
 SEX : MALE

CHEMICAL INTAKE CHANGES
 ALL ANIMALS

(SUMMARY)

PAGE : 4

Group Name	Administration (weeks)									
	46	50	54	58	62	66	70			
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0
800 ppm	33 ± 2	33 ± 5	32 ± 2	31 ± 2	32 ± 2	31 ± 2	31 ± 2	31 ± 2	31 ± 2	3
2400 ppm	94 ± 6	94 ± 5	93 ± 6	91 ± 5	91 ± 6	89 ± 5	90 ± 5	90 ± 5	90 ± 5	6
7200 ppm	261 ± 16	258 ± 19	254 ± 29	255 ± 23	253 ± 23	260 ± 27	268 ± 41	268 ± 41	268 ± 41	41

(HAN300)

BALS 4

Group Name	Administration (weeks)									
	74	78	82	86	90	94	98			
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0	0 ± 0	0
800 ppm	31 ± 3	32 ± 2	31 ± 2	32 ± 3	32 ± 3	33 ± 6	34 ± 5			
2400 ppm	91 ± 5	91 ± 13	90 ± 7	90 ± 8	92 ± 10	95 ± 13	101 ± 18			
7200 ppm	272 ± 48	279 ± 33	265 ± 30	260 ± 41	274 ± 52	280 ± 70	291 ± 108			
(HNS300)										
BALS 4										

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
UNIT : mg/kg/d a y
REPORT TYPE : A1 104
SEX : MALE

CHEMICAL INTAKE CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration (weeks)	
	102	104
Control	0 ± 0	0 ± 0
800 ppm	35 ± 6	35 ± 7
2400 ppm	105 ± 27	104 ± 17
7200 ppm	287 ± 92	288 ± 66

TABLE F 2

CHEMICAL INTAKE CHANGES: FEMALE

Group Name	Administration (weeks)						
	1	2	3	4	5	6	7
Control	0± 0	0± 0	0± 0	0± 0	0± 0	0± 0	0± 0
800 ppm	109± 29	114± 49	93± 19	94± 27	98± 40	90± 28	91± 29
2400 ppm	290± 79	264± 83	259± 83	261± 72	263± 107	251± 90	234± 69
7200 ppm	706± 68	606± 34	583± 133	537± 108	508± 53	480± 41	499± 105

(HAN360)

BATS 4

Group Name	Administration (weeks)													
	8	9	10	11	12	13	14							
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0							
800 ppm	82 ± 26	90 ± 37	84 ± 28	85 ± 25	86 ± 27	83 ± 24	80 ± 22							
2400 ppm	222 ± 60	233 ± 75	206 ± 55	215 ± 65	199 ± 59	215 ± 76	201 ± 62							
7200 ppm	462 ± 141	437 ± 57	422 ± 84	413 ± 61	413 ± 124	419 ± 108	411 ± 136							

(HAN300)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10Cr1j[F344/DuCr1j]
 UNIT : mg/kg/day
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 9

Group Name	Administration (weeks)									
	18	22	26	30	34	38	42			
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0
800 ppm	73 ± 21	78 ± 23	75 ± 20	72 ± 18	66 ± 17	68 ± 18	68 ± 18	68 ± 18	68 ± 18	18
2400 ppm	197 ± 58	207 ± 71	200 ± 63	183 ± 49	174 ± 42	175 ± 48	176 ± 56	176 ± 56	176 ± 56	56
7200 ppm	424 ± 122	414 ± 149	420 ± 123	398 ± 92	394 ± 82	399 ± 95	402 ± 94	402 ± 94	402 ± 94	94

(HAN300)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr101.[F344/DuCr1]
 UNIT : mg/kg/d a y
 REPORT TYPE : A1 I04
 SEX : FEMALE

CHEMICAL INTAKE CHANGES (SUMMARY)
 ALL ANIMALS

PAGE : 10

Group Name	Administration (weeks)						
	46	50	54	58	62	66	70
Control	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0
800 ppm	58 ± 12	59 ± 15	54 ± 14	52 ± 13	55 ± 16	54 ± 15	49 ± 10
2400 ppm	181 ± 51	181 ± 59	159 ± 50	153 ± 47	142 ± 40	139 ± 37	134 ± 35
7200 ppm	387 ± 61	419 ± 129	398 ± 110	385 ± 90	386 ± 91	374 ± 78	412 ± 107

(HAN300) BATS 4

CHEMICAL INTAKE CHANGES (SUMMARY)
ALL ANIMALS

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
UNIT : mg/kg/d a y
REPORT TYPE : AI 104
SEX : FEMALE

PAGE : 11

Group Name	Administration (weeks)									
	74	78	82	86	90	94	98			
Control	0±	0	0±	0	0±	0	0±	0	0±	0
800 ppm	48±	13	46±	14	44±	10	44±	9	46±	10
2400 ppm	138±	37	128±	33	130±	59	129±	42	132±	47
7200 ppm	412±	133	423±	111	436±	121	485±	109	536±	125

(HAN300)

BATS 4

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
UNIT : mg/kg/d a y
REPORT TYPE : AI 104
SEX : FEMALE

CHEMICAL INTAKE CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration (weeks)	
	102	104
Control	0 ± 0	0 ± 0
800 ppm	47 ± 12	47 ± 11
2400 ppm	142 ± 57	138 ± 45
7200 ppm	561 ± 150	610 ± 143

TABLE G 1

HEMATOLOGY: MALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1]
 MEASURE TIME : 1
 SEX : MALE
 REPORT TYPE : A1
 HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)
 PAGE : 1

Group Name	No. of Animals	RED BLOOD CELL 10 ⁶ /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV fl	MCH pg	MCHC g/dl	PLATELET 10 ³ /μl
Control	40	7.81±	13.6±	38.8±	50.0±	17.4±	34.9±	1041±
800 ppm	45	8.18±	14.4±	40.6±	50.5±	17.8±	35.3±	1019±
2400 ppm	38	8.46±	14.8±	41.6±	49.2±	17.4±	35.4±	962±
7200 ppm	40	8.39±	14.7±	40.8±	48.7±	17.5±	35.9±	901±

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett

(HCL070)

BATS 4

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1]
MEASURE TIME : 1
SEX : MALE

REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (105W)

PAGE : 2

Group Name	NO. of Animals	RETICULOCYTE %
Control	40	5.5± 4.8
800 ppm	45	5.0± 5.4
2400 ppm	38	4.0± 2.3
7200 ppm	40	3.2± 1.9**

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01

Test of Dunnett

(HCLO70)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1i[F344/DuCr1]
 MEASURE. TIME : 1
 SEX : MALE
 REPORT TYPE : A1
 HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)
 PAGE : 3

Group Name	NO. of Animals	WBC 1 O ³ /μl	Differential		WBC (%)		MONO	EOSINO	BASO	OTHER
			NEUTRO	LYMPHO						
Control	40	8.84 ± 6.07	49 ± 10	42 ± 10	6 ± 2	1 ± 1	0 ± 0	1 ± 1	0	1 ± 1
800 ppm	45	6.74 ± 1.85	47 ± 7	45 ± 7	6 ± 1	2 ± 1	0 ± 0	1 ± 1	0	1 ± 1
2400 ppm	38	6.91 ± 1.38	46 ± 8	46 ± 9	5 ± 1	2 ± 1	0 ± 0	1 ± 1	0	1 ± 1
7200 ppm	40	6.29 ± 1.72	46 ± 7	46 ± 7	5 ± 1	2 ± 1	0 ± 0	1 ± 1	0	1 ± 1

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL070)

BATS 4

TABLE G 2

HEMATOLOGY: FEMALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 MEASURE. TIME : 1
 SEX : FEMALE
 REPORT TYPE : AI

HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)

PAGE : 4

Group Name	NO. of Animals	RED BLOOD CELL 10 ⁶ /μl	HEMOGLOBIN g/dl	HEMATOCRIT %	MCV fl	MCH p g	MCHC g/dl	PLATELET 10 ³ /μl
Control	37	7.84±	14.9±	40.5±	52.2±	19.0±	36.6±	782±
800 ppm	38	7.80±	14.8±	40.1±	53.2±	19.4±	36.7±	709±
2400 ppm	42	7.66±	14.4±	39.1±	51.4±	18.8±	36.6±	815±
7200 ppm	33	7.17±	13.6±	37.0±	51.9±	19.0±	36.7±	886±

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01

Test of Dunnett

(HCL070)

BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 MEASURE. TIME : 1
 SEX : FEMALE
 REPORT TYPE : AI

HEMATOLOGY (SUMMARY)
 ALL ANIMALS (105W)
 PAGE : 5

Group Name	NO. of Animals	RETICULOCYTE %
Control	37	4.7 ± 7.8
800 ppm	38	4.8 ± 7.7
2400 ppm	42	4.0 ± 3.7
7200 ppm	33	4.1 ± 2.0**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL070)

BATS 4

Group Name	NO. of Animals	WBC 10 ³ /μl	NEUTRO	Differential	WBC (%)	LYMPHO	MONO	EOSINO	BASO	OTHER
Control	37	4.42± 3.21	41±	13	51±	13	5±	1	2±	1± 1
800 ppm	38	7.14± 10.00	37±	14	48±	17	5±	2	2±	1 8± 24
2400 ppm	42	4.87± 3.68	40±	13	52±	13	5±	2	2±	1 1± 1
7200 ppm	33	3.84± 3.18	50±	12*	42±	12*	6±	1	2+	1± 0

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01

Test of Dunnett

(HCL070)

BALS 4

TABLE H 1

BIOCHEMISTRY: MALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]
 MEASURE. TIME : 1
 SEX : MALE
 REPORT TYPE : A1

PAGE : 1

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

Group Name	No. of Animals	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T-BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Control	40	6.7±	2.8±	0.7±	0.18±	154±	195±	148±
800 ppm	45	6.6±	2.9±	0.8±	0.14±	160±	149±	104±
2400 ppm	38	6.7±	2.9±	0.8±	0.14±	159±	127±	79±
7200 ppm	40	6.5±	3.0±	0.9±	0.15±	147±	123±	65±

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL074)

BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]
 MEASURE, TIME : 1
 SEX : MALE
 REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

PAGE : 2

Group Name	No. of Animals	PHOSPHOLIPID mg/dl	AST IU/l	ALT IU/l	LDH IU/l	ALP IU/l	G-GTP IU/l	CK IU/l
Control	40	284 ± 73	106 ± 74	42 ± 22	181 ± 54	267 ± 205	7 ± 3	120 ± 73
800 ppm	45	223 ± 68**	106 ± 43	48 ± 20	219 ± 68**	170 ± 45**	3 ± 1**	108 ± 31
2400 ppm	38	190 ± 36**	116 ± 35**	56 ± 21*	209 ± 50	188 ± 43**	3 ± 1**	109 ± 25
7200 ppm	40	186 ± 60**	137 ± 88**	61 ± 26**	240 ± 205*	190 ± 89**	3 ± 3**	135 ± 215

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01

Test of Dunnett

(HCL074)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1i[F344/DuCr1i]
 MEASURE. TIME : 1
 SEX : MALE
 REPORT TYPE : A1

PAGE : 3

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg/dl	CREATININE mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHORUS mg/dl
Control	40	20.3 ± 8.2	0.7 ± 0.2	142 ± 2	3.5 ± 0.2	105 ± 2	10.6 ± 0.5	4.2 ± 0.9
800 ppm	45	19.2 ± 4.1	0.6 ± 0.1	143 ± 1	3.6 ± 0.3	105 ± 2	10.4 ± 0.4	4.1 ± 0.5
2400 ppm	38	18.0 ± 2.4	0.6 ± 0.1	143 ± 1	3.6 ± 0.3	105 ± 1	10.3 ± 0.2**	4.1 ± 0.5
7200 ppm	40	19.9 ± 9.9	0.6 ± 0.1**	143 ± 2	3.5 ± 0.4	104 ± 2	10.3 ± 0.5**	4.1 ± 1.0

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL074)

BATS 4

TABLE H 2

BIOCHEMISTRY: FEMALE

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr1Cr-1,1[F344/DuCr-1]

MEASURE. TIME : 1

SEX : FEMALE

REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (105W)

PAGE : 4

Group Name	NO. of Animals	TOTAL PROTEIN g/dl	ALBUMIN g/dl	A/G RATIO	T. BILIRUBIN mg/dl	GLUCOSE mg/dl	T-CHOLESTEROL mg/dl	TRIGLYCERIDE mg/dl
Control	38	6.9±	3.5±	1.0±	0.16±	151±	135±	106±
800 ppm	38	6.9±	3.5±	1.0±	0.40±	146±	129±	109±
2400 ppm	42	6.9±	3.4±	1.0±	0.15±	147±	119±	66±
7200 ppm	33	6.5±	3.4±	1.1±	0.13±	139±	119±	58±

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(HCL074)

BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 MEASURE. TIME : 1
 SEX : FEMALE
 REPORT TYPE : A1
 BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)
 PAGE : 5

Group Name	No. of Animals	PHOSPHOLIPID mg/dl	AST IU/l	ALT IU/l	LDH IU/l	ALP IU/l	G-GTP IU/l	CK IU/l
Control	38	245 ± 77	140 ± 115	55 ± 32	253 ± 268	136 ± 121	2 ± 1	100 ± 36
800 ppm	38	241 ± 70	229 ± 242**	77 ± 42**	389 ± 728**	169 ± 159	3 ± 2	104 ± 37
2400 ppm	42	219 ± 45	168 ± 84**	61 ± 25*	262 ± 92*	131 ± 50	2 ± 1	110 ± 82
7200 ppm	33	218 ± 49*	147 ± 55	44 ± 13	239 ± 80	188 ± 372	2 ± 3**	110 ± 63

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL074)

BATS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10Cr1j[F344/DuCr1j]
 MEASURE. TIME : 1
 SEX : FEMALE
 REPORT TYPE : AI

PAGE : 6

BIOCHEMISTRY (SUMMARY)
 ALL ANIMALS (105W)

Group Name	NO. of Animals	UREA NITROGEN mg/dl	CREATININE mg/dl	SODIUM mEq/l	POTASSIUM mEq/l	CHLORIDE mEq/l	CALCIUM mg/dl	INORGANIC PHOSPHORUS mg/dl
Control	38	17.1±	0.6±	141±	3.6±	104±	10.5±	3.9±
800 ppm	38	16.9±	0.5±	141±	3.6±	104±	10.5±	3.8±
2400 ppm	42	17.6±	0.5±	141±	3.6±	104±	10.4±	4.0±
7200 ppm	33	27.0±	0.6±	141±	3.8±	104±	10.5±	4.7±

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01

Test of Dunnett

(HCL074)

BATS 4

TABLE I 1

URINALYSIS: MALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 MEASURE. TIME : 1
 SEX : MALE
 REPORT TYPE : A1

PAGE : 1

URINALYSIS

Group Name	NO. of Animals	pH								Protein --- ± + 2+ 3+ 4+	Glucose		Ketone body		Bilirubin								
			5.0	6.0	6.5	7.0	7.5	8.0	8.5		CHII	--- ± + 2+ 3+ 4+	CHII	--- ± + 2+ 3+ 4+	CHII	--- + 2+ 3+	CHII						
Control	40	0	3	4	9	14	10	0	0	0	0	0	0	0	37	3	0	0	0	39	1	0	0
800 ppm	45	0	0	3	6	23	12	1	0	0	0	0	0	0	43	2	0	0	0	44	1	0	0
2400 ppm	38	0	0	1	9	16	12	0	0	0	0	0	0	0	32	6	0	0	0	38	0	0	0
7200 ppm	40	0	3	4	6	15	12	0	0	0	0	0	0	0	30	10	0	0	0	40	0	0	0

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of CHI SQUARE

(HCL101)

BATS 4

URINALYSIS

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr101[F344/DuCr1]

MEASURE. TIME : 1

SEX : MALE

REPORT TYPE : A1

PAGE : 2

Group Name	No. of Animals	Occult blood - ± + 2+ 3+	CH	Urobilinogen ± + 2+ 3+ 4+	CH
Control	40	36 1 0 1 2		40 0 0 0 0	
800 ppm	45	44 0 0 0 1		45 0 0 0 0	
2400 ppm	38	37 0 1 0 0		38 0 0 0 0	
7200 ppm	40	28 1 2 3 6		40 0 0 0 0	

Test of CHI SQUARE

** : P ≤ 0.01

* : P ≤ 0.05

Significant difference :

(HCL101)

BATS 4

TABLE I 2

URINALYSIS: FEMALE

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr1j[F344/DuCr1j]

MEASURE. TIME : 1

SEX : FEMALE

REPORT TYPE : A1

URINALYSIS

PAGE : 3

Group Name	No. of Animals	pH	5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHL	Protein --- ± + 2+ 3+ 4+	Glucose --- ± + 2+ 3+ 4+	CHL	Ketone body -- ± + 2+ 3+ 4+	CHL	Bilirubin --- + 2+ 3+	CHL
Control	38	0	1	5	6	16	9	1			0 1 1 10 18 8	38 0 0 0 0 0		17 21 0 0 0 0		38 0 0 0	
800 ppm	38	0	2	4	8	8	14	2			0 0 3 7 18 10	38 0 0 0 0 0		12 25 1 0 0 0		36 1 0 1	
2400 ppm	43	0	2	11	9	11	10	0			0 0 2 8 19 14	43 0 0 0 0 0		10 32 0 1 0 0		43 0 0 0	
7200 ppm	33	0	6	9	6	5	4	3	*		0 0 0 0 11 22	33 0 0 0 0 0	**	17 16 0 0 0 0		33 0 0 0	

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of CHI SQUARE

(HCL101)

BATS 4

STUDY NO. : 0641 URINALYSIS

ANIMAL : RAT F344/DuCr101[F344/DuCr1]

MEASURE. TIME : 1

SEX : FEMALE

REPORT TYPE : AI

PAGE : 4

Group Name	No. of Animals	Occult blood - ± + 2+ 3+	CH1	Urobilinogen ± + 2+ 3+ 4+	CH2
Control	38	38 0 0 0 0		38 0 0 0 0	
800 ppm	38	35 0 1 0 2		37 1 0 0 0	
2400 ppm	43	35 1 0 4 3	*	43 0 0 0 0	
7200 ppm	33	5 1 0 0 27	**	33 0 0 0 0	

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of CHI SQUARE

(HCL101)

BATS 4

TABLE K 1

ORGAN WEIGHT, ABSOLUTE: MALE

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr1j[F344/DuCr1j]

REPORT TYPE : AI

SEX : MALE

UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 1

Group Name	NO. of Animals	Body Weight	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	40	401 ± 45	0.076 ± 0.019	2.832 ± 0.974	1.239 ± 0.097	1.404 ± 0.183	2.864 ± 0.579
800 ppm	45	402 ± 38	0.106 ± 0.222	2.715 ± 1.097	1.238 ± 0.097	1.367 ± 0.146	2.740 ± 0.312
2400 ppm	38	406 ± 26	0.085 ± 0.096	2.763 ± 0.839	1.228 ± 0.092	1.345 ± 0.110	2.675 ± 0.172
7200 ppm	40	369 ± 60**	0.079 ± 0.073	2.142 ± 0.935**	1.152 ± 0.107**	1.245 ± 0.090**	2.714 ± 0.282

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett

(HCL040)

BAIS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 REPORT TYPE : A1
 SEX : MALE
 UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

PAGE : 2

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	40	1.158± 0.552	11.774± 1.703	2.104± 0.054
800 ppm	45	0.933± 0.403**	10.539± 1.113**	2.105± 0.041
2400 ppm	38	0.885± 0.282**	10.166± 0.914**	2.108± 0.038
7200 ppm	40	0.680± 0.113**	9.046± 1.367**	2.078± 0.037*

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(ICL040)

BATS 4

TABLE K 2

ORGAN WEIGHT, ABSOLUTE: FEMALE

STUDY NO. : 0641
 ORGAN WEIGHT: ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 REPORT TYPE : A1
 SEX : FEMALE
 UNIT: g

PAGE : 3

Group Name	No. of Animals	Body Weight	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	38	263 ± 31	0.069 ± 0.007	0.129 ± 0.021	0.886 ± 0.089	0.976 ± 0.172	1.819 ± 0.163
800 ppm	38	264 ± 30	0.070 ± 0.007	0.142 ± 0.097	0.903 ± 0.076	1.065 ± 0.442	1.864 ± 0.165
2400 ppm	42	267 ± 29	0.072 ± 0.008	0.163 ± 0.231	0.890 ± 0.068	0.977 ± 0.078	1.952 ± 0.155**
7200 ppm	33	207 ± 25**	0.076 ± 0.041	0.119 ± 0.022	0.783 ± 0.083**	0.881 ± 0.056**	2.078 ± 0.244**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(ICL040)

BAS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 REPORT TYPE : A1
 SEX : FEMALE
 UNIT : g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	38	0.759 ± 0.901	6.814 ± 1.095	1.925 ± 0.041
800 ppm	38	1.236 ± 2.217	7.237 ± 1.153	1.913 ± 0.049
2400 ppm	42	0.666 ± 0.293	7.161 ± 1.116	1.921 ± 0.046
7200 ppm	33	0.478 ± 0.232**	5.858 ± 0.676**	1.869 ± 0.037**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL040)

BAIS 4

TABLE L 1

ORGAN WEIGHT, RELATIVE: MALE

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1]
REPORT TYPE : AI
SEX : MALE
UNIT: %

PAGE : 1

Group Name	No. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	40	401± 45	0.019± 0.006	0.710± 0.244	0.312± 0.041	0.354± 0.061	0.731± 0.238
800 ppm	45	402± 38	0.027± 0.057	0.673± 0.257	0.311± 0.044	0.345± 0.075	0.690± 0.129
2400 ppm	38	406± 26	0.021± 0.024	0.684± 0.228	0.303± 0.022	0.332± 0.031	0.660± 0.039
7200 ppm	40	369± 60**	0.022± 0.020	0.591± 0.261	0.317± 0.035	0.344± 0.045	0.751± 0.125*

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL042)

BAS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr10r1j[F344/DuCr1j]
 REPORT TYPE : AI
 SEX : MALE
 UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)
 SURVIVAL ANIMALS (105W)

PAGE : 2

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	40	0.291 ± 0.139	2.960 ± 0.501	0.531 ± 0.058
800 ppm	45	0.240 ± 0.156**	2.647 ± 0.433**	0.529 ± 0.057
2400 ppm	38	0.219 ± 0.072**	2.508 ± 0.199**	0.521 ± 0.031
7200 ppm	40	0.188 ± 0.033**	2.485 ± 0.400**	0.576 ± 0.081**

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett

(ICL042)

BALS 4

TABLE L 2

ORGAN WEIGHT, RELATIVE: FEMALE

STUDY NO. : 0641

ANIMAL : RAT F344/DuCr1Cr1i[F344/DuCr1]

REPORT TYPE : A1

SEX : FEMALE

UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 3

Group Name	No. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	38	263 ± 31	0.027 ± 0.005	0.049 ± 0.007	0.340 ± 0.032	0.376 ± 0.069	0.703 ± 0.117
800 ppm	38	264 ± 30	0.027 ± 0.004	0.054 ± 0.035	0.345 ± 0.043	0.411 ± 0.191	0.714 ± 0.113
2400 ppm	42	267 ± 29	0.027 ± 0.005	0.059 ± 0.074	0.337 ± 0.039	0.371 ± 0.053	0.740 ± 0.100**
7200 ppm	33	207 ± 25**	0.038 ± 0.020**	0.057 ± 0.008**	0.382 ± 0.040**	0.433 ± 0.063**	1.028 ± 0.268**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(HCL042)

BALS 4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
 REPORT TYPE : A1
 SEX : FEMALE
 UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)
 SURVIVAL ANIMALS (105W)

PAGE : 4

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	38	0.289 ± 0.325	2.608 ± 0.376	0.745 ± 0.109
800 ppm	38	0.505 ± 0.978	2.759 ± 0.468	0.734 ± 0.092
2400 ppm	42	0.255 ± 0.121	2.707 ± 0.458	0.730 ± 0.089
7200 ppm	33	0.235 ± 0.129	2.854 ± 0.328	0.919 ± 0.133**

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(ICL042)

BALS 4

TABLE M 1

HISTOPATHOLOGICAL FINDINGS:

NON-NEOPLASTIC LESIONS:

MALE: ALL ANIMALS

STUDY NO. : 0641
 ANIMAL : RAT F344/duCr1j[F344/duCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS -NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 1

Organ	Findings	Group Name											
		No. of Animals on Study				Control				800 μm			
		Grade				50				50			
		1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
		50				50				2400 μm			

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCrjCrj[F344/DuCrj]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 2

Organ	Findings	Group Name No. of Animals on Study				Control				800 μ m				2400 μ m				7200 μ m			
		50				50				50				50				50			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Respiratory system)																					
nasal cavit																					
	mineralization	28 (56)	0 (0)	0 (0)	0 (0)	<50>	25 (50)	1 (2)	0 (0)	<50>	32 (64)	0 (0)	0 (0)	<50>	32 (64)	0 (0)	0 (0)	25 (50)	0 (0)	0 (0)	0 (0)
	eosinophilic change:olfactory epithelium	38 (76)	7 (14)	0 (0)	0 (0)	<50>	42 (84)	5 (10)	0 (0)	<50>	37 (74)	9 (18)	0 (0)	<50>	34 (68)	13 (26)	0 (0)	34 (68)	13 (26)	0 (0)	0 (0)
	eosinophilic change:respiratory epithelium	11 (22)	0 (0)	0 (0)	0 (0)	<50>	17 (34)	0 (0)	0 (0)	<50>	19 (38)	0 (0)	0 (0)	<50>	17 (34)	0 (0)	0 (0)	17 (34)	0 (0)	0 (0)	0 (0)
	inflammation:foreign body	15 (30)	0 (0)	0 (0)	0 (0)	<50>	15 (30)	0 (0)	0 (0)	<50>	16 (32)	0 (0)	0 (0)	<50>	14 (28)	0 (0)	0 (0)	14 (28)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:olfactory epithelium	12 (24)	0 (0)	0 (0)	0 (0)	<50>	7 (14)	0 (0)	0 (0)	<50>	6 (12)	1 (2)	0 (0)	<50>	10 (20)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)
	respiratory metaplasia:gland	50 (100)	0 (0)	0 (0)	0 (0)	<50>	50 (100)	0 (0)	0 (0)	<50>	48 (96)	0 (0)	0 (0)	<50>	47 (94)	0 (0)	0 (0)	47 (94)	0 (0)	0 (0)	0 (0)
	squamous cell metaplasia:respiratory epithelium	6 (12)	1 (2)	0 (0)	0 (0)	<50>	2 (4)	0 (0)	0 (0)	<50>	1 (2)	1 (2)	0 (0)	<50>	4 (8)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)
larynx																					
	inflammation	2 (4)	0 (0)	0 (0)	0 (0)	<50>	0 (0)	0 (0)	0 (0)	<50>	1 (2)	0 (0)	0 (0)	<50>	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference : * : P \leq 0.05 ** : P \leq 0.01 Test of Chi Square

(JPT150)

BAIS4

STUDY NO. : 0641
 ANIMAL : RAT F344/duCr-IOT-Ij[F344/duCr-Ij]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 3

Organ	Findings	Group Name No. of Animals on Study				Control				800 μm				2400 μm				7200 μm			
		Grade				50				50				50				50			
		1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Respiratory system}																					
lung	congestion	2 (4)	1 (2)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	0 (0)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	2 (4)	0 (0)	0 (0)	0 (0)
		1 (2)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration	1 (2)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
		2 (4)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	accumulation of foamy cells	4 (8)	2 (4)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
		0 (0)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia	4 (8)	2 (4)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
		0 (0)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{hematopoietic system}																					
bone marrow	granulation	0 (0)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		9 (18)	2 (4)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	4 (8)	2 (4)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
	increased hematopoiesis	9 (18)	2 (4)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	4 (8)	2 (4)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
		0 (0)	0 (0)	0 (0)	0 (0)	<50> (0)	<50> (0)	<50> (0)	<50> (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BAIS4

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105#)

PAGE : 4

Organ	Findings	Control				800 μm				2400 μm				7200 μm						
		50				50				50				50						
		1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)			
(Hematopoietic system)																				
bone marrow	decreased hematopoiesis	0	0	0	0	<50>	0	0	0	0	<50>	0	0	0	0	<50>	1	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
spleen	congestion	2	0	0	0	<50>	0	0	0	0	<50>	0	0	0	0	<50>	0	0	0	0
		(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	deposit of hemosiderin	0	0	0	0		0	0	0	0		0	0	0	0		1	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	inflammatory infiltration	0	0	0	0		0	0	0	0		1	0	0	0		0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	fibrosis:focal	0	0	0	0		0	0	0	0		0	0	0	0		1	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	extramedullary hematopoiesis	12	5	0	0		13	1	0	0		11	2	0	0		7	1	0	0
		(24)	(10)	(0)	(0)	(26)	(2)	(0)	(0)	(0)	(22)	(4)	(0)	(0)	(0)	(0)	(14)	(2)	(0)	(0)
(Circulatory system)																				
heart	thrombus	0	0	0	0	<50>	2	0	0	0	<50>	0	0	0	0	<50>	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe																				
a : Number of animals examined at the site																				
b : Number of animals with lesion																				
(c) c : b / a * 100																				
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square																				

(IPT150)

BAIS4

STUDY NO. : 0641
 ANIMAL : RAT F344/duCr1Cr1j [F344/duCr1j]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 5

Organ	Findings	Group Name No. of Animals on Study											
		Control				800 μ m				2400 μ m			
		1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Circulatory system}													
heart	necrosis:focal	0	0	0	0	0	0	0	0	1	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	mineralization	0	1	0	0	0	0	0	0	0	0	0	0
		(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	myocardial fibrosis	15	1	0	0	14	0	0	0	19	1	0	0
		(30)	(2)	(0)	(0)	(28)	(0)	(0)	(0)	(38)	(2)	(0)	(0)
artery/aort	mineralization	0	1	0	0	0	0	0	0	0	0	0	0
		(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Digestive system}													
tongue	squamous cell hyperplasia	0	0	0	0	1	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
stomach	erosion:forestomach	1	0	0	0	1	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
{Significant difference ; * : P \leq 0.05 ** : P \leq 0.01 Test of Chi Square													

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

BAIS4

HISTOPATHOLOGICAL FINDINGS -NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

STUDY NO. : 0641
ANIMAL : RAT F344/duCr:1Cr1j[F344/duCr:j]
REPORT TYPE : A1
SEX : MALE

PAGE : 6

Organ	Findings	Group Name No. of Animals on Study				Control				800 µm				2400 µm				7200 µm			
		Grade				50				50				50				50			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																					
stomach																					
	ulcer:forestomach	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:forestomach	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	erosion:glandular stomach	5 (10)	2 (4)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	ulcer:glandular stomach	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:glandular stomach	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	mineralization:glandular stomach	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
small intes																					
	ulcer	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	erosion	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BAIS4

HISTOPATHOLOGICAL FINDINGS -NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

STUDY NO. : 0641
ANIMAL : RAT F344/duCr1Cr1j[F344/duCr1j]
REPORT TYPE : A1
SEX : MALE

PAGE : 7

Organ	Findings	Group Name No. of Animals on Study				Control				800 µm				2400 µm				7200 µm			
		Grade				50				50				50				50			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}																					
small intes																					
necrosis		0	0	0	0	<50>				0	0	0	0	<50>				0	0	0	0
		(0)	(0)	(0)	(0)					(0)	(0)	(0)	(0)					(0)	(0)	(0)	(0)
																		1	0	0	0
																		(2)	(0)	(0)	(0)
large intes																					
mineralization		0	0	0	0	<50>				0	0	0	0	<50>				0	0	0	0
		(0)	(0)	(0)	(0)					(0)	(0)	(0)	(0)					(0)	(0)	(0)	(0)
																		1	0	0	0
																		(2)	(0)	(0)	(0)
Liver																					
herniation		3	0	0	0	<50>				5	0	0	0	<50>				6	0	0	0
		(6)	(0)	(0)	(0)					(10)	(0)	(0)	(0)					(12)	(0)	(0)	(0)
																		3	0	0	0
																		(6)	(0)	(0)	(0)
necrosis:central		0	0	0	0					0	1	0	0					0	0	0	0
		(0)	(0)	(0)	(0)					(0)	(2)	(0)	(0)					(0)	(0)	(0)	(0)
necrosis:focal		1	0	0	0					0	0	0	0					2	0	0	0
		(2)	(0)	(0)	(0)					(0)	(0)	(0)	(0)					(4)	(0)	(0)	(0)
																		0	0	0	0
																		(0)	(0)	(0)	(0)
fatty change:peripheral		0	1	0	0					0	0	0	0					0	0	0	0
		(0)	(2)	(0)	(0)					(0)	(0)	(0)	(0)					(0)	(0)	(0)	(0)
																		0	1	0	0
																		(0)	(2)	(0)	(0)
cyst		0	0	0	0					0	0	0	0					0	0	0	0
		(0)	(0)	(0)	(0)					(0)	(0)	(0)	(0)					(0)	(0)	(0)	(0)
																		1	0	0	0
																		(2)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BATS4

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)

PAGE : 8

Organ	Findings	Group Name No. of Animals on Study				Control				800 ppm				2400 ppm				7200 ppm			
		50				50				50				50				50			
		1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)				
{Digestive system}	liver	granulation	1 (2)	0 (0)	0 (0)	0 (0)	<50>	0 (0)	0 (0)	0 (0)	0 (0)	<50>	0 (0)	0 (0)	0 (0)	0 (0)	<50>	0 (0)	0 (0)	0 (0)	
		inflammatory cell nest	38 (76)	1 (2)	0 (0)	0 (0)	45 (90)	0 (0)	0 (0)	0 (0)	41 (82)	0 (0)	0 (0)	0 (0)	41 (82)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
		extramedullary hematopoiesis	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
		acidophilic cell focus	16 (32)	2 (4)	0 (0)	0 (0)	10 (20)	1 (2)	0 (0)	0 (0)	12 (24)	1 (2)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
		basophilic cell focus	4 (8)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	9 (18)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
		spongiosis hepatitis	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
		bile duct hyperplasia	44 (88)	0 (0)	0 (0)	0 (0)	47 (94)	0 (0)	0 (0)	0 (0)	45 (90)	0 (0)	0 (0)	0 (0)	48 (96)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
		bile ductular proliferation	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	

Grade	1 : Slight	2 : Moderate	3 : Marked	4 : Severe
< a >	a : Number of animals examined at the site			
b	b : Number of animals with lesion			
(c)	c : b / a * 100			
Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square				

(IPT 150)

BAIS4

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrJ]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

PAGE : 9

Organ	Findings	Group Name No. of Animals on Study											
		Control				800 ppm				2400 ppm			
		1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Digestive system}													
liver	cholangiofibrosis	<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	1	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	focal fatty change	<50>				<50>				<50>			
		0	0	0	0	1	0	0	0	2	1	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(2)	(0)	(0)
pancreas	atrophy:focal	<50>				<50>				<50>			
		3	1	0	0	3	0	0	0	6	1	0	0
		(6)	(2)	(0)	(0)	(6)	(0)	(0)	(0)	(12)	(2)	(0)	(0)
	islet cell hyperplasia	<50>				<50>				<50>			
		1	1	0	0	0	0	0	0	2	0	0	0
		(2)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
{Urinary system}													
kidney	cyst	<50>				<50>				<50>			
		0	0	0	0	2	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hyaline droplet	<50>				<50>				<50>			
		0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)

Grade	1 : Slight	2 : Moderate	3 : Marked	4 : Severe
< a >	a : Number of animals examined at the site			
b	b : Number of animals with lesion			
(c)	c : b / a * 100			
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square				

(HPT150) BAIS4

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1j [F344/DuCr1j]
 REPORT TYPE : AI
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 10

Group Name No. of Animals on Study Grade	Findings	Control				800 μ m				2400 μ m				7200 μ m			
		50				50				50				50			
		1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
(Urinary system)																	
kidney	scar	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	chronic nephropathy	9 (18)	21 (42)	11 (22)	3 (6)	21 (42)	15 (30)	9 (18)	0 (0)	28 (56)	12 (24)	2 (4)	0 (0)	24 (48)	7 (14)	3 (6)	0 (0)
	papillary necrosis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	37 (74)	0 (0)	0 (0)	0 (0)
	mineralization:papilla	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	mineralization:pelvis	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
dilatation:tubular lumen																	
urothelial hyperplasia:pelvis																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	
inflammation:papilla																	

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 a : Number of animals examined at the site
 b : Number of animals with lesion
 c : b / a * 100
 Significant difference : * : P \leq 0.05 ** : P \leq 0.01 Test of Chi Square

(HPT150)

BAIS4

STUDY NO. : 0641
ANIMAL : RAT F344/duCrjCrj [F344/duCrj]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

PAGE : 11

Organ	Findings	Group Name No. of Animals on Study															
		Control				800 μm				2400 μm				7200 μm			
		1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
{Urinary system}																	
urin bladd	inflammation	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
		<50>															
		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
{Endocrine system}																	
pituitary	angiectasis	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
		<49>															
		4 (8)	0 (0)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)
	cyst	12 (24)	9 (18)	2 (4)	0 (0)	14 (28)	8 (16)	0 (0)	0 (0)	12 (24)	9 (18)	3 (6)	0 (0)	13 (26)	4 (8)	2 (4)	0 (0)
		<50>															
		2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
	Rathke pouch	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		<50>															
		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Aberrant craniopharyngeal tissue}																	

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BATS4

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

PAGE : 13

Group Name	No. of Animals on Study	Control				800 μ m				2400 μ m				7200 μ m			
		50				50				50				50			
Grade	Findings	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Endocrine system)																	
adrenal																	
	hyperplasia: medulla	3 (6)	3 (6)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	2 (4)	0 (0)	0 (0)	1 (2)	3 (6)	1 (2)	0 (0)
	focal fatty change: cortex	1 (2)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	4 (8)	1 (2)	0 (0)	0 (0)
(Reproductive system)																	
testis																	
	mineralization	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	arteritis	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	interstitial cell hyperplasia	8 (16)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	9 (18)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)
prostate																	
	inflammation	6 (12)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe

a : Number of animals examined at the site

b : Number of animals with lesion

c : b / a * 100

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

BAIS4

STUDY NO. : 0641
 ANIMAL : RAT F344/duCr1Cr1j [F344/duCr1j]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 14

Organ	Findings	Group Name No. of Animals on Study											
		Control				800 µm				2400 µm			
		1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Reproductive system}													
prostate	hyperplasia	7 (14)	1 (2)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	4 (8)	1 (2)	0 (0)	0 (0)
												2 (4)	0 (0)
												0 (0)	0 (0)
mammary gl	galactoceles	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
												0 (0)	0 (0)
												0 (0)	0 (0)
{Nervous system}													
brain	hemorrhage	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
												0 (0)	0 (0)
												0 (0)	0 (0)
spinal cord	hemorrhage	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
												0 (0)	0 (0)
												0 (0)	0 (0)
{Special sense organs/appendage}													
eye	cataract	8 (16)	1 (2)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)
												4 (8)	0 (0)
												0 (0)	0 (0)

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

PAGE : 15

[illegible]

Grade	1 : Slight	2 : Moderate	3 : Marked	4 : Severe
< a >	a : Number of animals examined at the site			
b	b : Number of animals with lesion			
(c)	c : b / a * 100			
Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$				
Test of Chi Square				

(HPT150)

BAIS4

Organ	Findings	Group Name																			
		No. of Animals on Study				Control				800 μm				2400 μm				7200 μm			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4				
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)				
{Musculoskeletal system}																					
bone	osteosclerosis	1	0	0	0	<50>	0	0	0	0	0	0	0	0	0	0	0				
		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)				
{Body cavities}																					
peritoneum	inflammatory infiltration	0	0	0	0	<50>	0	0	0	0	0	0	0	0	0	0	0				
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)				
Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe																					
< a > a : Number of animals examined at the site																					
b b : Number of animals with lesion																					
(c) c : b / a * 100																					
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square																					
(HPT150)																					
BATS1																					

TABLE M 4

HISTOPATHOLOGICAL FINDINGS:

NON-NEOPLASTIC LESIONS:

FEMALE: ALL ANIMALS

PAGE : 17

BAIS4

STUDY NO. : 0641
 ANIMAL : RAT F344/DoCr1Cr1j[F344/DoCr1j]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 18

Organ	Findings	Group Name No. of Animals on Study				Control				800 ppm				2400 ppm				7200 ppm			
		Grade				50				50				50				50			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Respiratory system)																					
nasal cavit	respiratory metaplasia:olfactory epithelium	2	0	0	0	<50>	2	0	0	0	<50>	2	0	0	0	<50>	2	0	0	0	<50>
		(4)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)
respiratory metaplasia:gland	49	0	0	0	<50>	50	0	0	0	<50>	49	0	0	0	<50>	49	0	0	0	<50>	
	(98)	(0)	(0)	(0)	(100)	(100)	(0)	(0)	(0)	(0)	(98)	(0)	(0)	(0)	(0)	(98)	(0)	(0)	(0)	(0)	
lung	squamous cell metaplasia:respiratory epithelium	5	0	0	0	<50>	1	0	0	0	<50>	0	0	0	0	<50>	0	0	0	0	<50>
		(10)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
lung	congestion	4	0	0	0	<50>	1	0	0	0	<50>	0	0	0	0	<50>	0	0	0	0	<50>
		(8)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	inflammatory infiltration	1	0	0	0	<50>	2	0	0	0	<50>	0	0	0	0	<50>	0	0	0	0	<50>
		(2)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	accumulation of foamy cells	1	0	0	0	<50>	1	0	0	0	<50>	1	0	0	0	<50>	1	0	0	0	<50>
		(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)
	bronchiolar-alveolar cell hyperplasia	0	2	0	0	<50>	1	1	0	0	<50>	0	1	0	0	<50>	0	1	0	0	<50>
		(0)	(4)	(0)	(0)	(0)	(2)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
(Hematopoietic system)																					
bone marrow	granulation	1	0	0	0	<50>	3	0	0	0	<50>	3	1	1	0	<50>	3	1	1	0	<50>
		(2)	(0)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(0)	(6)	(2)	(2)	(0)	(0)	(6)	(2)	(2)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(HPT150)

BATS4

STUDY NO. : 0641
 ANIMAL : RAT F344/duCr:1Cr:1j [F344/duCr:1j]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 19

Organ	Findings	Group Name No. of Animals on Study												7200 ppm											
		Control				800 ppm				2400 ppm				50											
		1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)								
(Hematopoietic system)																									
bone marrow	increased hematopoiesis	6 (12)	0 (0)	0 (0)	0 (0)	<50> (6)	0 (0)	0 (0)	0 (0)	<50> (10)	0 (0)	0 (0)	0 (0)	<50> (14)	0 (0)	0 (0)	0 (0)								
		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)								
spleen	congestion	0 (0)	0 (0)	0 (0)	0 (0)	<50> (0)	0 (0)	0 (0)	0 (0)	<50> (2)	0 (0)	0 (0)	0 (0)	<50> (0)	0 (0)	0 (0)	0 (0)								
		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)								
	deposit of hemosiderin	17 (34)	3 (6)	2 (4)	0 (0)	14 (28)	1 (2)	2 (4)	0 (0)	16 (32)	2 (4)	1 (2)	0 (0)	16 (32)	5 (10)	1 (2)	0 (0)								
		(Circulatory system)																							
heart	thrombus	0 (0)	0 (0)	0 (0)	0 (0)	<50> (0)	0 (0)	0 (0)	0 (0)	<50> (0)	0 (0)	0 (0)	0 (0)	<50> (0)	1 (2)	0 (0)	0 (0)								
		Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square																							
Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe																									
a : Number of animals examined at the site																									
b : Number of animals with lesion																									
c : b / a * 100																									
(HPT150)																									
EATS4																									

(HPT150)

BAIS4

STUDY NO. : 0641
 ANIMAL : RAT F344/DoCr1j[F344/DoCrj]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 20

Organ	Findings	Group Name No. of Animals on Study											
		Control				800 µm				2400 µm			
		1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Circulatory system)													
heart	myocardial fibrosis	5 (10)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)
(Digestive system)													
oral cavity	inflammatory infiltration	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	squamous cell hyperplasia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
tongue	ulcer	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	squamous cell hyperplasia	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
stomach	erosion-forestomach	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

(IPT150)

BATS4

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

PAGE : 21

[illegible]

Grade	1 : Slight	2 : Moderate	3 : Marked	4 : Severe
a >	a : Number of animals examined at the site			
b	b : Number of animals with lesion			
(c)	c : b / a * 100			

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

(IIPT150)

BAIS4

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)

ANIMAL : RAT F344/DuCr1j [F344/DuCrj]

REPORT TYPE : A1

SEX : FEMALE

PAGE : 22

Organ	Findings	Group Name No. of Animals on Study					Control					800 μm					2400 μm					7200 μm						
		Grade					50					50					50					50						
		1	2	3	4	(%)	1	2	3	4	(%)	1	2	3	4	(%)	1	2	3	4	(%)	1	2	3	4	(%)		
{Digestive system}	liver	herniation	9	0	0	0		7	0	0	0		7	0	0	0		8	0	0	0		8	0	0	0		
			(18)	(0)	(0)	(0)		(14)	(0)	(0)	(0)		(14)	(0)	(0)	(0)		(16)	(0)	(0)	(0)		(16)	(0)	(0)	(0)		
	poliosis-like lesion	1	0	0	0		0	0	0	0		0	0	0	0		0	0	0	0		0	0	0	0			
(2)		(0)	(0)	(0)		(0)	(0)	(0)	(0)		(0)	(0)	(0)	(0)		(0)	(0)	(0)	(0)		(0)	(0)	(0)	(0)				
	necrosis:central	0	0	1	0		0	0	1	0		0	0	1	0		0	0	1	0		0	0	0	0			
(0)		(0)	(2)	(0)		(0)	(0)	(2)	(0)		(0)	(0)	(2)	(0)		(0)	(0)	(2)	(0)		(0)	(0)	(0)	(0)				
	necrosis:focal	0	0	0	0		3	0	0	0		3	0	0	0		2	0	0	0		2	0	0	0			
(0)		(0)	(0)	(0)		(6)	(0)	(0)	(0)		(6)	(0)	(0)	(0)		(4)	(0)	(0)	(0)		(4)	(0)	(0)	(0)				
	fatty change:central	0	0	1	0		0	0	0	0		0	0	0	0		0	1	0	0		0	1	0	0			
(0)		(0)	(2)	(0)		(0)	(0)	(0)	(0)		(0)	(0)	(0)	(0)		(0)	(2)	(0)	(0)		(0)	(2)	(0)	(0)				
	fatty change:peripheral	1	1	0	0		0	0	0	0		1	1	0	0		0	0	0	0		0	0	0	0			
(2)		(2)	(0)	(0)		(0)	(0)	(0)	(0)		(2)	(2)	(0)	(0)		(0)	(0)	(0)	(0)		(0)	(0)	(0)	(0)				
	granulation	0	0	0	0		0	1	0	0		0	0	0	0		0	0	0	0		0	0	0	0			
(0)		(0)	(0)	(0)		(0)	(2)	(0)	(0)		(0)	(0)	(0)	(0)		(0)	(0)	(0)	(0)		(0)	(0)	(0)	(0)				
	inflammatory cell nest	28	4	0	0		31	1	0	0		27	4	0	0		27	2	0	0		27	2	0	0			
(56)		(8)	(0)	(0)		(62)	(2)	(0)	(0)		(54)	(8)	(0)	(0)		(54)	(4)	(0)	(0)		(54)	(4)	(0)	(0)				

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe

a : Number of animals examined at the site

b : Number of animals with lesion

c : b / a * 100

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT 150)

BAIS4

HISTOPATHOLOGICAL FINDINGS -NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1J [F344/DuCr1J]
REPORT TYPE : A1
SEX : FEMALE

PAGE : 23

Organ	Findings	Group Name																			
		No. of Animals on Study				Control				800 µm											
		Grade				50				50											
		1	2	3	4	1	2	3	4	1	2	3	4								
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)				
		50				50				50				2400 µm				7200 µm			
		1				1				1				1				1			
		2				2				2				2				2			
		3				3				3				3				3			
		4				4				4				4				4			
		(%)				(%)				(%)				(%)				(%)			
{Digestive system}																					
liver	acidophilic cell focus	5	0	0	0	<50>	<50>	<50>	<50>	5	1	0	0	<50>	<50>	0	2	0	0 *		
		(10)	(0)	(0)	(0)	(12)	(2)	(0)	(0)	(10)	(2)	(0)	(0)	(10)	(2)	(0)	(0)	(4)	(0)	(0)	
	basophilic cell focus	25	0	0	0	<50>	<50>	<50>	<50>	25	0	0	0	<50>	<50>	18	0	0	0		
		(50)	(0)	(0)	(0)	(52)	(0)	(0)	(0)	(50)	(2)	(0)	(0)	(50)	(2)	(0)	(0)	(0)	(0)	(0)	
	bile duct hyperplasia	28	0	0	0	<50>	<50>	<50>	<50>	19	0	0	0	<50>	<50>	22	0	0	0		
		(56)	(0)	(0)	(0)	(48)	(0)	(0)	(0)	(38)	(0)	(0)	(0)	(38)	(0)	(0)	(0)	(0)	(0)	(0)	
	bile ductular proliferation	0	0	0	0	<50>	<50>	<50>	<50>	0	0	0	0	<50>	<50>	1	0	0	0		
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	
pancreas	atrophy:focal	1	0	0	0	<50>	<50>	<50>	<50>	2	0	0	0	<50>	<50>	2	0	0	0		
		(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	
	islet cell hyperplasia	0	0	0	0	<50>	<50>	<50>	<50>	1	0	0	0	<50>	<50>	0	0	0	0		
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	
{Urinary system}																					
kidney	cyst	0	0	0	0	<50>	<50>	<50>	<50>	0	1	0	0	<50>	<50>	2	0	0	0		
		(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(HPT150)

BA154

STUDY NO. : 0641
 ANIMAL : RAT F344/DoCr1Cr1j[F344/DoCr1j]
 REPORT TYPE : AI
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 24

Organ	Findings	Group Name No. of Animals on Study											
		Control				800 ppm				2400 ppm			
		1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
{Urinary system}													
Kidney	lyaline droplet	1	0	0	0	0	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	scar	0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	chronic nephropathy	17	4	1	0	19	4	1	0	19	0	0	0
		(34)	(8)	(2)	(0)	(38)	(8)	(2)	(0)	(38)	(0)	(0)	(0)
	hydronephrosis	0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	papillary necrosis	0	0	0	0	0	0	0	0	17	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(34)	(0)	(0)	(0)
	mineralization:papilla	0	0	0	0	1	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	mineralization:pelvis	1	0	0	0	0	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	mineralization:cortex	0	0	0	0	0	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BATS4

HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS (SUMMARY)

PAGE : 25

BAIS4

Organ	Findings	Group Name No. of Animals on Study Grade				Control				800 ppm				2400 ppm				7200 ppm			
		1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)	1 (%)	2 (%)	3 (%)	4 (%)
(Endocrine system)																					
pituitary	hyperplasia	5 (10)	5 (10)	0 (0)	0 (0)	4 (8)	3 (6)	0 (0)	0 (0)	<50>				4 (8)	1 (2)	0 (0)	0 (0)	<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)
thyroid	C-cell hyperplasia	6 (12)	1 (2)	0 (0)	0 (0)	7 (14)	2 (4)	0 (0)	0 (0)	<50>				5 (10)	0 (0)	0 (0)	0 (0)	<50>			
		2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
adrenal	angiectasis	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	<50>				2 (4)	0 (0)	0 (0)	0 (0)	<50>			
		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
hyperplasia:cortical cell	hyperplasia:medulla	5 (10)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	<50>				1 (2)	0 (0)	0 (0)	0 (0)	<50>			
		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)

Grade	1 : Slight	2 : Moderate	3 : Marked	4 : Severe
< a >	a : Number of animals examined at the site			
b	b : Number of animals with lesion			
(c)	c : b / a * 100			
Significant difference :	* : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square			
(IPT150)	BATS4			

STUDY NO. : 0641
 ANIMAL : RAT F344/duCr1c1J[F344/duCr1]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 27

Organ	Findings	Group Name No. of Animals on Study				Control				800 ppm				2400 ppm				7200 ppm			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Endocrine system)																					
adrenal	focal fatty change:cortex	6 (12)	2 (4)	0 (0)	0 (0)	<50>	3 (6)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)
{Reproductive system}																					
ovary	cyst	1 (2)	0 (0)	0 (0)	0 (0)	<50>	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
uterus	cystic endometrial hyperplasia	2 (4)	0 (0)	0 (0)	0 (0)	<50>	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)
mammary gl	cyst	0 (0)	0 (0)	0 (0)	0 (0)	<50>	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Special sense organs/appendage}																					
eye	cataract	4 (8)	1 (2)	0 (0)	0 (0)	<50>	3 (6)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)
Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe																					
< a > a : Number of animals examined at the site b : Number of animals with lesion (c) c : b / a * 100 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square																					
(IPT150)																					

BATS4

STUDY NO. : 0541
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 28

Organ	Findings	Group Name				Control				800 ppm				2400 ppm				7200 ppm			
		No. of Animals on Study				Grade				50				50				50			
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
		(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
(Special sense organs/appendage)																					
eye	retinal atrophy	15	6	4	0	<50>	<50>	<50>	<50>	15	3	5	0	6	4	2	0	16	10	3	0
		(30)	(12)	(8)	(0)	(30)	(6)	(10)	(0)	(12)	(8)	(4)	(0)	(32)	(20)	(6)	(0)				
keratitis	5	0	0	0	0	2	0	0	0	2	0	0	0	1	0	0	0	0	0	1	0 *
		(10)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)
iritis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Harder gl	hyperplasia	0	0	0	0	<50>	<50>	<50>	<50>	0	0	0	0	1	0	0	0	0	0	0	0
		(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
(Musculoskeletal system)																					
muscle	mineralization	1	0	0	0	<50>	<50>	<50>	<50>	0	0	0	0	0	0	0	0	0	0	0	0
		(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
bone	osteosclerosis	5	0	0	0	<50>	<50>	<50>	<50>	2	0	0	0	2	2	0	0	2	0	0	0
		(10)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(4)	(4)	(0)	(0)	(4)	(0)	(0)
Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe																					
a : Number of animals examined at the site																					
b : Number of animals with lesion																					
c : b / a * 100																					
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square																					
(UPT150)																					
BATS4																					

TABLE P 1

NEOPLASTIC LESIONS-INCIDENCE AND
STATISTICAL ANALYSIS: MALE

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

STUDY No. : 0641
ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
SEX : MALE

PAGE : 1

Group Name	Control	800 ppm	2400 ppm	7200 ppm
SITE : skin/appendage TUMOR : squamous cell papilloma				
Tumor rate	4/50(8.0)	0/50(0.0)	1/50(2.0)	0/50(0.0)
Overall rates(a)	10.00	0.0	2.63	0.0
Adjusted rates(b)	4/40(10.0)	0/45(0.0)	1/38(2.6)	0/40(0.0)
Terminal rates(c)				
Statistical analysis				
Peto test	P =			
Standard method(d)	P = 0.9725			
Prevalence method(d)	P =			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.0856			
Fisher Exact test(e)		P = 0.0587	P = 0.1811	P = 0.0587
SITE : skin/appendage TUMOR : keratoacanthoma				
Tumor rate	6/50(12.0)	2/50(4.0)	2/50(4.0)	1/50(2.0)
Overall rates(a)	15.00	4.44	2.63	2.50
Adjusted rates(b)	6/40(15.0)	2/45(4.4)	1/38(2.6)	1/40(2.5)
Terminal rates(c)				
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3775			
Prevalence method(d)	P = 0.9621			
Combined analysis(d)	P = 0.9554			
Cochran-Armitage test(e)	P = 0.0957			
Fisher Exact test(e)		P = 0.1343	P = 0.1343	P = 0.0559
SITE : subcutis TUMOR : fibroma				
Tumor rate	6/50(12.0)	1/50(2.0)	6/50(12.0)	4/50(8.0)
Overall rates(a)	12.20	2.22	10.53	10.00
Adjusted rates(b)	4/40(10.0)	1/45(2.2)	4/38(10.5)	4/40(10.0)
Terminal rates(c)				
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6908			
Prevalence method(d)	P = 0.3527			
Combined analysis(d)	P = 0.4684			
Cochran-Armitage test(e)	P = 0.9855			
Fisher Exact test(e)		P = 0.0559	P = 0.6202	P = 0.3703

(HPT360A)

BAIS4

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

STUDY No. : 0641
ANIMAL : RAT F344/DuCr1J1[F344/DuCr1J]
SEX : MALE

PAGE : 2

Group Name	Control	800 ppm	2400 ppm	7200 ppm
SITE : Lung				
TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	3/50(6.0)	1/50(2.0)	1/50(2.0)
Adjusted rates(b)	7.50	6.57	2.53	0.0
Terminal rates(c)	3/40(7.5)	3/45(6.7)	1/38(2.6)	0/40(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1415			
Prevalence method(d)	P = 0.9781			
Combined analysis(d)	P = 0.8614			
Cochran-Armitage test(e)	P = 0.2555			
Fisher Exact test(e)		P = 0.6611	P = 0.3087	P = 0.3087
SITE : spleen				
TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	4/50(8.0)	2/50(4.0)	7/50(14.0)	0/50(0.0)
Adjusted rates(b)	7.50	2.22	5.26	0.0
Terminal rates(c)	3/40(7.5)	1/45(2.2)	2/38(5.3)	0/40(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.7552			
Prevalence method(d)	P = 0.9371			
Combined analysis(d)	P = 0.9428			
Cochran-Armitage test(e)	P = 0.1137			
Fisher Exact test(e)		P = 0.3389	P = 0.2623	P = 0.0587
SITE : pancreas				
TUMOR : islet cell adenoma				
Tumor rate				
Overall rates(a)	3/50(6.0)	5/50(10.0)	2/50(4.0)	4/50(8.0)
Adjusted rates(b)	7.50	11.11	4.76	10.00
Terminal rates(c)	3/40(7.5)	5/45(11.1)	0/38(0.0)	4/40(10.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.4160			
Prevalence method(d)	P = 0.4160			
Combined analysis(d)	P = 0.9052			
Cochran-Armitage test(e)	P = 0.9052			
Fisher Exact test(e)		P = 0.3575	P = 0.5000	P = 0.5000

(HPT350A)

BAIS4

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

STUDY No. : 0641
ANIMAL : RAT F344/DuCr101i1[F344/DuCr.i]
SEX : MALE

PAGE : 3

Group Name	Control	800 ppm	2400 ppm	7200 ppm
<p>SITE : pancreas TUMOR : islet cell adenocarcinoma</p>				
Tumor rate				
Overall rates(a)	1/50(2.0)	3/50(6.0)	1/50(2.0)	3/50(6.0)
Adjusted rates(b)	2.50	6.67	2.63	7.50
Terminal rates(c)	1/40(2.5)	3/45(6.7)	1/38(2.6)	3/40(7.5)
Statistical analysis				
Peto test	P = -----			
Standard method(d)	P = 0.2165			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.4694			
Cochran-Armitage test(e)				
Fisher Exact test(e)	P = 0.3087		P = 0.7525	P = 0.3087
<p>SITE : pancreas TUMOR : islet cell adenoma, islet cell adenocarcinoma</p>				
Tumor rate				
Overall rates(a)	4/50(8.0)	8/50(16.0)	3/50(6.0)	7/50(14.0)
Adjusted rates(b)	10.00	17.78	7.14	17.50
Terminal rates(c)	4/40(10.0)	8/45(17.8)	1/38(2.6)	7/40(17.5)
Statistical analysis				
Peto test	P = -----			
Standard method(d)	P = 0.2846			
Prevalence method(d)	P = -----			
Combined analysis(d)	P = 0.5822			
Cochran-Armitage test(e)				
Fisher Exact test(e)	P = 0.1783		P = 0.5000	P = 0.2623
<p>SITE : pituitary gland TUMOR : adenoma</p>				
Tumor rate				
Overall rates(a)	13/49(26.5)	7/50(14.0)	6/50(12.0)	8/50(16.0)
Adjusted rates(b)	27.50	15.56	15.00	17.50
Terminal rates(c)	10/39(25.6)	7/45(15.6)	5/38(13.2)	7/40(17.5)
Statistical analysis				
Peto test	P = 0.5007			
Standard method(d)	P = 0.7361			
Prevalence method(d)	P = 0.7375			
Combined analysis(d)	P = 0.4484			
Cochran-Armitage test(e)				
Fisher Exact test(e)	P = 0.0961		P = 0.0564	P = 0.1502

(HPT350A)

BALSA

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

STUDY No. : 0641
ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCr1j]
SEX : MALE

PAGE : 4

Group Name	Control	800 ppm	2400 ppm	7200 ppm
SITE : pituitary gland TUMOR : adenocarcinoma				
Tumor rate				
Overall rates(a)	1/49(2.0)	1/50(2.0)	2/50(4.0)	3/50(6.0)
Adjusted rates(b)	2.56	2.22	5.26	5.00
Terminal rates(c)	1/39(2.6)	1/45(2.2)	2/38(5.3)	2/40(5.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1345			
Prevalence method(d)	P = 0.2426			
Combined analysis(d)	P = 0.1111			
Cochran-Armitage test(e)	P = 0.2198			
Fisher Exact test(e)		P = 0.7576	P = 0.5077	P = 0.3163
SITE : pituitary gland TUMOR : adenoma, adenocarcinoma				
Tumor rate				
Overall rates(a)	14/49(28.6)	8/50(16.0)	8/50(16.0)	11/50(22.0)
Adjusted rates(b)	30.00	17.78	20.00	22.50
Terminal rates(c)	11/39(28.2)	8/45(17.8)	7/38(18.4)	9/40(22.5)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2342			
Prevalence method(d)	P = 0.6103			
Combined analysis(d)	P = 0.5031			
Cochran-Armitage test(e)	P = 0.8835			
Fisher Exact test(e)		P = 0.1032	P = 0.1032	P = 0.3013
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	12/50(24.0)	12/50(24.0)	8/50(16.0)	7/50(14.0)
Adjusted rates(b)	25.00	26.67	21.05	16.67
Terminal rates(c)	10/40(25.0)	12/45(26.7)	8/38(21.1)	6/40(15.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.8906			
Combined analysis(d)	P = 0.9165			
Cochran-Armitage test(e)	P = 0.1560			
Fisher Exact test(e)		P = 0.5924	P = 0.2270	P = 0.1540

(HPT350A)

BAIS4

Group Name	Control	800 µm	2400 µm	7200 µm
SITE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma				
Tumor rate				
Overall rates(a)	12/50(24.0)	13/50(26.0)	9/50(18.0)	8/50(16.0)
Adjusted rates(b)	25.00	28.89	21.05	19.05
Terminal rates(c)	10/40(25.0)	13/45(28.9)	8/38(21.1)	7/40(17.5)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6947			
Prevalence method(d)	P = 0.8459			
Combined analysis(d)	P = 0.8773			
Cochran-Armitage test(e)	P = 0.2231			
Fisher Exact test(e)		P = 0.5000	P = 0.3121	P = 0.2270
SITE : adrenal gland TUMOR : pheochromocytoma				
Tumor rate				
Overall rates(a)	4/50(8.0)	4/50(8.0)	3/50(6.0)	5/50(10.0)
Adjusted rates(b)	7.50	8.89	7.14	12.20
Terminal rates(c)	3/40(7.5)	4/45(8.9)	2/38(5.3)	4/40(10.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 1.0000 ?			
Prevalence method(d)	P = 0.2410			
Combined analysis(d)	P = 0.3277			
Cochran-Armitage test(e)	P = 0.6542			
Fisher Exact test(e)		P = 0.6425	P = 0.5000	P = 0.5000
SITE : adrenal gland TUMOR : pheochromocytoma, pheochromocytoma:malignant				
Tumor rate				
Overall rates(a)	5/50(10.0)	5/50(10.0)	3/50(6.0)	6/50(12.0)
Adjusted rates(b)	10.00	11.11	7.14	12.20
Terminal rates(c)	4/40(10.0)	5/45(11.1)	2/38(5.3)	4/40(10.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3001			
Prevalence method(d)	P = 0.3898			
Combined analysis(d)	P = 0.3358			
Cochran-Armitage test(e)	P = 0.6659			
Fisher Exact test(e)		P = 0.6297	P = 0.3575	P = 0.5000

(HPT360A)

BAIS4

Group Name	Control	800 ppm	2400 ppm	7200 ppm
	SITE : testis			
	TUMOR : interstitial cell tumor			
Tumor rate				
Overall rates(a)	35/50(70.0)	31/50(62.0)	31/50(62.0)	20/50(40.0)
Adjusted rates(b)	85.00	67.39	71.79	50.00
Terminal rates(c)	34/40(85.0)	30/45(66.7)	27/38(71.1)	20/40(50.0)
Statistical analysis				
Peto test				
Standard method(d)	P = -----			
Prevalence method(d)	P = 0.9994			
Combined analysis(d)	P = -----			
Cochran-Armitage test(e)	P = 0.0017**			
Fisher Exact test(e)		P = 0.2634	P = 0.2634	P = 0.0023**
(HPT350A)				
BATS4				

(a) : Number of tumor-bearing animals/number of animals examined at the site.
 (b) : Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
 (c) : Observed tumor incidence at terminal kill.
 (d) : Beneath the control incidence are the P-values associated with the trend test.
 Standard method : Death analysis
 Prevalence method : Incidental tumor test
 Combined analysis : Death analysis + Incidental tumor test
 (e) : The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
 ? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
 ----- : There is no data which should be statistical analysis.
 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01
 N.C.:Statistical value cannot be calculated and was not significant.

TABLE P 2

NEOPLASTIC LESIONS-INCIDENCE AND
STATISTICAL ANALYSIS: FEMALE

Group Name	Control	800 ppm	2400 ppm	7200 ppm
SITE : spleen TUMOR : mononuclear cell leukemia				
Tumor rate				
Overall rates(a)	4/50(8.0)	7/50(14.0)	5/50(10.0)	5/50(10.0)
Adjusted rates(b)	5.26	10.53	7.14	3.03
Terminal rates(c)	2/38(5.3)	4/38(10.5)	3/42(7.1)	1/33(3.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1545			
Prevalence method(d)	P = 0.7892			
Combined analysis(d)	P = 0.4100			
Cochran-Armitage test(e)	P = 0.9342			
Fisher Exact test(e)		P = 0.2623	P = 0.5000	P = 0.5000
SITE : pituitary gland TUMOR : adenoma				
Tumor rate				
Overall rates(a)	12/50(24.0)	17/50(34.0)	16/50(32.0)	14/50(28.0)
Adjusted rates(b)	14.63	29.27	33.33	30.30
Terminal rates(c)	5/38(13.2)	11/38(28.9)	14/42(33.3)	10/33(30.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.9062			
Prevalence method(d)	P = 0.1222			
Combined analysis(d)	P = 0.3917			
Cochran-Armitage test(e)	P = 0.9734			
Fisher Exact test(e)		P = 0.1891	P = 0.2522	P = 0.4100
SITE : pituitary gland TUMOR : adenoma,adenocarcinoma				
Tumor rate				
Overall rates(a)	14/50(28.0)	19/50(38.0)	17/50(34.0)	14/50(28.0)
Adjusted rates(b)	17.50	31.71	35.71	30.30
Terminal rates(c)	6/38(15.8)	12/38(31.6)	15/42(35.7)	10/33(30.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.9510			
Prevalence method(d)	P = 0.2005			
Combined analysis(d)	P = 0.5784			
Cochran-Armitage test(e)	P = 0.6023			
Fisher Exact test(e)		P = 0.1976	P = 0.3329	P = 0.5880

(HPT360A)

BAISA

Group Name	Control	800 ppm	2400 ppm	7200 ppm
SITE : thyroid TUMOR : C-cell adenoma				
Tumor rate				
Overall rates(a)	6/50(12.0)	8/50(16.0)	11/50(22.0)	4/50(8.0)
Adjusted rates(b)	13.16	17.39	22.45	12.12
Terminal rates(c)	5/38(13.2)	5/38(13.2)	9/42(21.4)	4/33(12.1)
Statistical analysis				
Peto test	P =			
Standard method(d)	P =			
Prevalence method(d)	P = 0.7582			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.3210			
Fisher Exact test(e)	P = 0.3871		P = 0.1434	P = 0.3703
SITE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma				
Tumor rate				
Overall rates(a)	6/50(12.0)	8/50(16.0)	12/50(24.0)	4/50(8.0)
Adjusted rates(b)	13.16	17.39	22.92	12.12
Terminal rates(c)	5/38(13.2)	5/38(13.2)	9/42(21.4)	4/33(12.1)
Statistical analysis				
Peto test	P =			
Standard method(d)	P = 0.3509			
Prevalence method(d)	P = 0.7579			
Combined analysis(d)	P = 0.7545			
Cochran-Armitage test(e)	P = 0.3209			
Fisher Exact test(e)	P = 0.3871		P = 0.0961	P = 0.3703
SITE : adrenal gland TUMOR : pheochromocytoma				
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	1/50(2.0)	3/50(6.0)
Adjusted rates(b)	2.33	2.04	2.38	7.69
Terminal rates(c)	0/38(0.0)	0/38(0.0)	1/42(2.4)	2/33(6.1)
Statistical analysis				
Peto test	P =			
Standard method(d)	P =			
Prevalence method(d)	P = 0.0800			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.1721			
Fisher Exact test(e)	P = 0.7525		P = 0.7525	P = 0.3087

(HPT360A)

BAIS4

STUDY No. : 0641
ANIMAL : RAT F344/DuCr10r1.1[F344/DuCr1]
SEX : FEMALE

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

PAGE : 9

Group Name	Control	800 µm	2400 µm	7200 µm
SITE : adrenal gland				
TUMOR : pheochromocytoma, pheochromocytoma:malignant				
Tumor rate	1/50(2.0)	1/50(2.0)	1/50(2.0)	4/50(8.0)
Overall rates(a)	2.33	2.04	2.38	10.26
Adjusted rates(b)	0/38(0.0)	0/38(0.0)	1/42(2.4)	3/33(9.1)
Terminal rates(c)				
Statistical analysis				
Peto test	P =			
Standard method(d)	P =			
Prevalence method(d)	P = 0.0284*			
Combined analysis(d)	P =			
Cochran-Armitage test(e)	P = 0.0573			
Fisher Exact test(e)		P = 0.7525	P = 0.7525	P = 0.1811
SITE : uterus				
TUMOR : endometrial stromal polyp				
Tumor rate	7/50(14.0)	5/50(10.0)	9/50(18.0)	5/50(10.0)
Overall rates(a)	14.29	10.53	19.05	15.15
Adjusted rates(b)	5/38(13.2)	4/38(10.5)	8/42(19.0)	5/33(15.2)
Terminal rates(c)				
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3536			
Prevalence method(d)	P = 0.5626			
Combined analysis(d)	P = 0.5630			
Cochran-Armitage test(e)	P = 0.6515			
Fisher Exact test(e)		P = 0.3798	P = 0.3929	P = 0.3798
SITE : mammary gland				
TUMOR : fibroadenoma				
Tumor rate	7/50(14.0)	7/50(14.0)	10/50(20.0)	4/50(8.0)
Overall rates(a)	14.00	13.04	20.93	12.12
Adjusted rates(b)	3/38(7.9)	4/38(10.5)	8/42(19.0)	4/33(12.1)
Terminal rates(c)				
Statistical analysis				
Peto test				
Standard method(d)	P = 0.5859			
Prevalence method(d)	P = 0.7653			
Combined analysis(d)	P = 0.7933			
Cochran-Armitage test(e)	P = 0.2934			
Fisher Exact test(e)		P = 0.6129	P = 0.2977	P = 0.2623

(HPT360A)

BAIS4

Group Name	Control	800 ppm	2400 ppm	7200 ppm
SITE : mammary gland TUMOR : adenoma, fibroadenoma, adenocarcinoma				
Tumor rate				
Overall rates (a)	11/50 (22.0)	10/50 (20.0)	11/50 (22.0)	6/50 (12.0)
Adjusted rates (b)	22.00	20.00	20.93	15.15
Terminal rates (c)	6/38 (15.8)	6/38 (15.8)	8/42 (19.0)	5/33 (15.2)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.2528			
Prevalence method (d)	P = 0.9141			
Combined analysis (d)	P = 0.8625			
Cochran-Armitage test (e)	P = 0.1712			
Fisher Exact test (e)		P = 0.5000	P = 0.5952	P = 0.1434
SITE : preputial/clitoral gland TUMOR : adenoma				
Tumor rate				
Overall rates (a)	3/50 (6.0)	3/50 (6.0)	1/50 (2.0)	2/50 (4.0)
Adjusted rates (b)	5.26	4.88	2.38	6.06
Terminal rates (c)	2/38 (5.3)	1/38 (2.6)	1/42 (2.4)	2/33 (6.1)
Statistical analysis				
Peto test				
Standard method (d)	P = 0.8633			
Prevalence method (d)	P = 0.3970			
Combined analysis (d)	P = 0.6076			
Cochran-Armitage test (e)	P = 0.6080			
Fisher Exact test (e)		P = 0.6611	P = 0.3087	P = 0.5000

(HPT360A)

BA154

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.
----- : There is no data which should be statistical analysis.
Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$
N.C.: Statistical value cannot be calculated and was not significant.

TABLE R

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER:

F344/DuCr1Cr1j FEMALE RATS

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN
BIOASSAY RESEARCH CENTER : F344/DuCrI CrIj FEMALE RATS

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Adrenal	2446			
Pheochromocytoma 1)		81	3.3	0 - 16
Pheochromocytoma:malignant 2)		22	0.9	0 - 6
1)+2)		103	4.2	0 - 18

49 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No. : 0043, 0059, 0061, 0063, 0065, 0067, 0095, 0104, 0115, 0130, 0141, 0158, 0162, 0189,
0205, 0210, 0224, 0242, 0246, 0267, 0269, 0278, 0284, 0288, 0296, 0318, 0328, 0342,
0347, 0365, 0371, 0399, 0401, 0417, 0421, 0437, 0448, 0457, 0461, 0497, 0535, 0560,
0579, 0610, 0612, 0667, 0675, 0686, 0691

TABLE S 1

CAUSE OF DEATH: MALE

STUDY NO. : 0641
ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCrJ]
SEX : MALE
PAGE : 1

COUSE OF DEATH (SUMMARY)
(O-105W)

Group Name	Control	800 ppm	2400 ppm	7200 ppm
Number of Dead and Moribund Animal	10	5	12	10
no microscop confirm	1	1	0	1
integumentary sy les	0	0	1	0
renal lesion	0	0	0	1
chronic nephropathy	1	0	0	0
tumor d:leukemia	1	1	5	0
tumor d:skin/app	1	0	1	0
tumor d:subcutis	1	0	2	0
tumor d:lung	0	0	0	1
tumor d:urin bladd	0	0	0	1
tumor d:pituitary	2	0	0	2
tumor d:thyroid	1	1	1	1
tumor d:adrenal	1	0	0	1
tumor d:brain	1	0	0	0
tumor d:Zymba l gl	0	0	1	1
tumor d:bone	0	1	1	0
tumor d:peritoneum	0	1	0	1

(B10120) BATS4

TABLE S 2

CAUSE OF DEATH: FEMALE

STUDY NO. : 0641
 ANIMAL : RAT F344/DuCr1Cr1J[F344/DuCr1J]
 SEX : FEMALE

CAUSE OF DEATH (SUMMARY)
 (0-105W)

PAGE : 2

Group Name	Control	800 ppm	2400 ppm	7200 ppm
Number of Dead and Moribund Animal	12	12	8	17
no microscop confirm	0	1	1	2
renal lesion	0	0	0	2
tumor d:leukemia	2	3	2	6
tumor d:thymus	1	0	0	0
tumor d:pituitary	7	6	2	2
tumor d:thyroid	0	0	1	0
tumor d:uterus	1	0	1	3
tumor d:mammary gl	0	1	1	1
tumor d:prep/cli gl	1	1	0	0
tumor d:Zymbal gl	0	0	0	1

(B10120)

BATS4

FIGURES

- FIGURE 1 SURVIVAL ANIMAL RATE OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL
- FIGURE 2 SURVIVAL ANIMAL RATE OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL
- FIGURE 3 BODY WEIGHT CHANGES OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL
- FIGURE 4 BODY WEIGHT CHANGES OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL
- FIGURE 5 FOOD CONSUMPTION CHANGES OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL
- FIGURE 6 FOOD CONSUMPTION CHANGES OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL
- FIGURE 7 WATER CONSUMPTION CHANGES OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL
- FIGURE 8 WATER CONSUMPTION CHANGES OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL




FIGURE 1 SURVIVAL ANIMAL RATE OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL




FIGURE 2 SURVIVAL ANIMAL RATE OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL




FIGURE 3 BODY WEIGHT CHANGES OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL




FIGURE 4 BODY WEIGHT CHANGES OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL




FIGURE 5 FOOD CONSUMPTION CHANGES OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY 2-AMINOETHANOL




FIGURE 6 FOOD CONSUMPTION CHANGES OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL




FIGURE 7 WATER CONSUMPTION CHANGES OF MALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL






FIGURE 8 WATER CONSUMPTION CHANGES OF FEMALE RATS IN THE 2-YEAR DRINKING WATER STUDY OF 2-AMINOETHANOL



Photograph 1
Kidney: Normal
Rat, Female, Control, Animal No. 0641-2007 (H&E)



Photograph 2
Kidney: Papillary necrosis (arrows)
Rat, Female, 7200ppm, Animal No. 0641-2304 (H&E)



Photograph 3
Kidney: Urothelial hyperplasia of pelvis (arrows)
Rat, Female, 7200ppm, Animal No. 0641-2313 (H&E)